[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hodgkin-lymphoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hodgkin-lymphoma":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,73,0,25,[9,45,80,107,127,162,185,258,279,300,323,343,376,394,421,460,495,524,546,578,697,720,748,767,788],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100632525","integration-of-adaptive-proton-therapy-in-pediatric-solid-tumors-and-hodgkins-lymphoma-100632525",false,"NCT07514819","Integration of Adaptive Proton Therapy in Pediatric Solid Tumors and Hodgkin's Lymphoma","Inclusion Criteria:\n\n* Participants diagnosed with solid tumors, including Rhabdomyosarcoma, Osteosarcoma, Ewing sarcoma, other sarcomas and carcinomas or also Hodgkin's lymphoma.\n* Participants who receive proton radiation therapy at St. Jude Children's Research Hospital.\n* Research participant or legal guardian\u002Frepresentative gives written informed consent.\n\nExclusion Criteria:\n\n* Participants who are not diagnosed with solid tumors or Hodgkin's lymphoma.\n* Participants who are diagnosed with Wilm's tumor or neuroblastoma\n* Participants who do not undergo proton therapy.\n* Participants who are prescribed equal or less than 5 fractions of proton therapy.\n* Participants with severe comorbid conditions that may impact imaging feasibility.\n* Inability to obtain written consent from research participant or legal guardian\u002Frepresentative.\n* Females of child-bearing potential cannot be pregnant or breast-feeding. Female participants \\>10 years of age or post-menarchal must have a negative serum or urine pregnancy test\n\nAll participants receiving proton therapy at St. Jude Children's Research Hospital will be screened for participation on this research protocol based on the Inclusion Criteria and the Exclusion Criteria. Qualified candidates will be selected during the consultation.","ALL",{"count":18,"type":19},100,"ESTIMATED","INTERVENTIONAL",[22],"NA","Pediatric patients receiving proton therapy for solid tumors or Hodgkin's lymphoma may experience anatomical changes during treatment that can affect proton therapy accuracy. This prospective single-arm study uses regular low-dose imaging to monitor these changes and adjust treatment plans as needed. Participants will receive weekly or every-other-week CT scans, with MRI when appropriate, to assess whether the original plan remains accurate. Treatment plans will be updated if tumor coverage decreases by more than 5% or if radiation dose to normal tissues increases by more than 10%; otherwise, the original plan will continue. The study aims to determine how often plan adjustments are needed and to identify which disease sites are most likely to experience significant anatomical changes during treatment.\n\nPrimary Objective:\n\n* Define the frequency of replanning necessary to ensure tumor coverage never falls below 95% (or 5% drop) of the prescribed daily dose in participants with intact (gross) tumors to keep the tumor control optimal throughout the multi-week treatment regimen.\n* Define the frequency of replanning necessary to ensure organs-at-risk (critical organs) do not deviate by more than 10% of the initially approved dose constraints to keep the normal tissue complication minimal throughout the multi-week treatment regimen.\n\nSecondary Objectives\n\n* Establish a cone beam CT (CBCT)-based framework for quantifying body surface changes throughout the treatment course. This goal will be achieved by developing a novel algorithm that detects and tracks external anatomical variations longitudinally, without requiring CBCT image enhancement, enabling precise assessment of daily participant setup consistency and anatomical stability.\n* Overcome daily CBCT quality limitations by generating synthetic CT images that accurately represent daily anatomy and support proton dose recalculation or verification planning. This goal will be achieved by developing a hybrid pipeline that integrates deep learning models with the deformable image registration algorithm, trained and validated on disease site-specific data. This will enable precise dose mapping and tissue density estimation, directly supporting adaptive planning decisions without the need of diagnostic- quality CT images.",[25,26,27,28,29,30,31],"Pediatric Solid Tumors","Rhabdomyosarcoma","Ewing Sarcoma","Osteosarcoma","Hodgkin Lymphoma","Bone Tumor","Soft Tissue Sarcoma","NOT_YET_RECRUITING","2026-06-30",{"date":35,"type":36},"2026-07-02","ACTUAL",{"date":38,"type":19},"2026-08",{"date":40,"type":19},"2031-08",{"name":42,"class":43},"St. Jude Children's Research Hospital","OTHER",1,{"id":46,"slug":47,"hasResults":12,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":16,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":20,"phases":57,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":73,"startDateStruct":74,"completionDateStruct":75,"leadSponsor":77,"locationsCount":79},"100594521","phase-1-a-vaccine-cmv-mva-triplex-vaccine-for-the-enhancement-of-cmv-specific-immunity-and-the-prevention-of-cmv-viremia-in-patients-undergoing-haploidentical-hematopoietic-stem-cell-transplant-100594521","NCT07020533","A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant","A Phase 1b Trial of CMV-MVA Triplex Vaccine in Haploidentical Stem Cell Donors and Recipients to Enhance CMV-Specific Immunity and Prevent CMV Viremia in Recipients of Hematopoietic Stem Cell Transplant","Inclusion Criteria:\n\n* DONORS: Documented informed consent of the participant. This can be done in person or informed consent can be obtained remotely.\n\n  * Remote consent, when appropriate, will be obtained per institutional guidelines.\n  * Assent, when appropriate, will be obtained per institutional guidelines.\n  * Adult subjects who require a legally authorized representative (LAR) will not be permitted to be enrolled under this protocol.\n* DONORS: Age: 18 - 75.\n* DONORS: Women of childbearing potential (WOCBP): negative urine or serum pregnancy test. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.\n* DONORS: Agreement by females and males of childbearing potential\\* to use an effective method of birth control (hormonal or barrier method) or abstain from heterosexual activity prior to study entry and for up to 90 days post-vaccination.\n\n  * Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for \\> 1 year (women only).\n* RECIPIENTS: Documented informed consent of the participant and\u002For legally authorized representative. This can be done in person or informed consent can be obtained remotely.\n\n  * Remote consent, when appropriate, will be obtained per institutional guidelines.\n  * Assent, when appropriate, will be obtained per institutional guidelines.\n  * Adult subjects who require a legally authorized representative (LAR) will not be permitted to be enrolled under this protocol.\n* RECIPIENTS: Participant must be willing to comply with study and\u002For follow-up procedures, including willingness to be followed for one year post-HCT.\n* RECIPIENTS: Age: 18 - 75.\n* RECIPIENTS: Planned peripheral blood stem cell (PBSC) or bone marrow (BM) HCT for the treatment of the following hematologic malignancies:\n\n  * Lymphoma (Hodgkin and Non-Hodgkin).\n  * Myelodysplastic syndrome.\n  * Acute lymphoblastic leukemia in first or second remission (for acute lymphoblastic leukemia\u002Flymphoblastic lymphoma, the disease status must be in hematologic remission by bone marrow and peripheral blood. Persistent lymphadenopathy on computed tomography (CT) or CT\u002Fpositron emission tomography(PET) scan without progression is allowed.)\n  * Acute myeloid leukemia in first or second remission.\n  * Chronic myelogenous leukemia in first chronic or accelerated phase, or in second chronic phase.\n  * Other hematologic malignancies judged appropriate by the clinical principal investigators (PIs), including chronic lymphocytic leukemia, myeloproliferative disorders and myelofibrosis. Patients with multiple myeloma and those with non-malignant disease such as aplastic anemia are excluded\\*\\*.\n\n    * Adult cases of multiple myeloma (MM) are excluded as HCT is not standard of care for MM and is only performed in very advanced cases with an associated high risk of relapse and non-relapse mortality (NRM). Adults with aplastic anemia are excluded because their standard management includes T cell depletion with agents such as antithymocyte globulin (ATG), which is not permissible on this protocol. Patients undergoing a second haploHCT are not eligible (patients who have undergone a previous autologous HCT are eligible).\n* RECIPIENTS: Patients receiving myeloablative (MA) or reduced intensity conditioning (RIC) are allowed.\n* RECIPIENTS: CMV seropositive.\n* RECIPIENTS: Eligible haploidentical donors will have 2-4 mismatches if human leukocyte antigen (HLA)-A, -B, -C, and -DRB1 typing is used; 2-5 mismatches if HLA-A, -B, -C, -DRB1, and -DQB1 typing is used; and 2-6 mismatches if HLA-A, -B, -C, -DRB1, -DQB1, and -DPB1 typing is used. A unidirectional mismatch in either the graft versus host or host versus graft direction is considered a mismatch. The donor and recipient must demonstrate that they are a full haplotype match by being identical at a minimum of one allele (at high resolution deoxyribonucleic acid \\[DNA\\]-based typing) at the following genetic loci: HLA-A, -B, -C, and DRB1 if 8 allele typing is used; HLA-A, -B, -C, -DRB1, and -DQB1 if 10 allele typing is used; and HLA-A, -B, -C, -DRB1-, DQB1, and -DPB1 is 12 allele typing is used.\n* RECIPIENTS: Planned HCT with minimal to no-T cell depletion of graft.\n* RECIPIENTS: Conditioning and immunosuppressive regimens according to institutional guidelines are permitted.\n* RECIPIENTS: Total bilirubin ≤ 1.5 X upper limit of normal (ULN) (unless has Gilbert's disease) (to be performed within 45 days prior to day 1 of protocol therapy).\n* RECIPIENTS: Aspartate aminotransferase (AST) =\\\u003C 2.5 x ULN (to be performed within 45 days prior to day 1 of protocol therapy).\n* RECIPIENTS: Alanine aminotransferase (ALT) =\\\u003C 2.5 x ULN (to be performed within 45 days prior to day 1 of protocol therapy).\n* RECIPIENTS: Estimated creatinine clearance acceptable per institutional guidelines (to be performed within 45 days prior to day 1 of protocol therapy).\n* RECIPIENTS: Left ventricular ejection fraction (LVEF) ≥ 50%.\n\n  * Note: To be performed within 45 days prior to day 1 of protocol therapy.\n* RECIPIENTS: If able to perform pulmonary function tests: forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC) and carbon monoxide diffusing capability (DLCO) (diffusion capacity) ≥ 50% of predicted (corrected for hemoglobin).\n\n  * If unable to perform pulmonary function tests: Oxygen (O2) saturation \\> 92% on room air.\n  * Note to be performed within 45 days prior to day 1 of protocol therapy.\n* RECIPIENTS: Seronegative for HIV antigen (Ag)\u002Fantibody (Ab) combination (combo), hepatitis c virus (HCV)\\*, active hepatitis b virus (HBV) (surface antigen negative) and syphilis (RPR) within 2 months of registration and no history of disseminated cutaneous human papillomavirus (HPV) related disease.\n\n  * If seropositive for HIV, HCV or HBV, nucleic acid quantitation must be performed. Viral load must be undetectable.\n* RECIPIENTS: Meets other institutional and federal requirements for infectious disease titer requirements.\n\n  * Note Infectious disease testing to be performed within 45 days prior to day 1 of protocol therapy.\n* RECIPIENTS: Women of childbearing potential (WOCBP): negative urine or serum pregnancy test. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required (to be performed within 45 days prior to day 1 of protocol therapy).\n* RECIPIENTS: Agreement by females and males of childbearing potential\\* to use an effective method of birth control (hormonal or barrier method) or abstain from heterosexual activity prior to study entry and up to 90 days post-HCT.\n\n  * Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for \\> 1 year (women only).\n\nExclusion Criteria:\n\n* DONORS: Any prior transplant to day 1 of protocol therapy (day 1 defined as the day after donors receive the Triplex vaccine).\n* DONORS: Chemotherapy, radiation therapy, biological therapy, immunotherapy within 21 days prior to day 1 of protocol therapy.\n* DONORS: Receipt of any vaccine (licensed or investigational) within 30 days prior to and after the study vaccine.\n* DONORS: Unfit to undergo standard stem cell mobilization and apheresis e.g. abnormal blood counts, history of stroke, uncontrolled hypertension.\n* DONORS: Sickling hemoglobinopathy including hemoglobin (Hb)SS, HbAS, HbSC.\n* DONORS: Donors with impaired cardiac function are excluded. Electrocardiography is routine for potential HCT donors over 60 years old and those with a history of heart disease. Subjects in whom cardiac function is abnormal (excluding 1st degree branch block, sinus bradycardia, sinus tachycardia or non-specific T wave changes) are ineligible for Triplex vaccination.\n* DONORS: Severe psychiatric illness. Mental deficiency sufficiently severe as to make compliance with the donation procedure unlikely and making informed consent impossible.\n* DONORS: Females only: Pregnant or breastfeeding.\n* DONORS: Any other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures.\n* DONORS: Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility\u002Flogistics).\n* RECIPIENTS: Any prior investigational CMV vaccine.\n* RECIPIENTS: Experimental anti-CMV chemotherapy in the last 6 months.\n* RECIPIENTS: Live attenuated vaccines (planned medications from the time of HCT to day 70 post-HCT).\n* RECIPIENTS: Medically indicated subunit (Engerix-B for HBV; Gardasil for HPV) or killed vaccines (e.g. influenza, pneumococcal, or allergy treatment with antigen injections) (planned medications from the time of HCT to day 70 post-HCT).\n* RECIPIENTS: Allergy treatment with antigen injections (planned medications from the time of HCT to day 70 post-HCT).\n* RECIPIENTS: Alemtuzumab or any equivalent in vivo T-cell depleting agent (or CD34+ selection) (planned medications from the time of HCT to day 70 post-HCT).\n* RECIPIENTS: Antiviral medications with known therapeutic effects on CMV such as ganciclovir (GCV)\u002Fvalganciclovir (VAL), foscarnet (FOS), cidofovir, CMX-001, maribavir. Acyclovir has no known therapeutic efficacy against CMV and is allowable as standard of care to prevent herpes simplex virus (HSV) (planned medications from the time of HCT to day 70 post-HCT).\n* RECIPIENTS: Prophylactic therapy with CMV immunoglobulin or prophylactic antiviral CMV treatment EXCEPT letermovir prophylaxis (prior to day 100) (planned medications from the time of HCT to day 70 post-HCT).\n* RECIPIENTS: Disease-based radiation therapy (not total body irradiation) (planned medications from the time of HCT to day 70 post-HCT).\n* RECIPIENTS: Other investigational product(s) - concurrent enrollment in other clinical trials using any investigational new drug (IND) drugs with unknown effects on CMV or with unknown toxicity profiles is prohibited (planned medications from the time of HCT to day 70 post-HCT).\n* RECIPIENTS: Other medications that might interfere with the evaluation of the investigational product (planned medications from the time of HCT to day 70 post-HCT).\n* RECIPIENTS: Patients with active autoimmune conditions requiring systemic immunosuppressive therapy within the previous 5 years.\n* RECIPIENTS: Patients considered by PI\u002Fconsenting physicians to have a complicated prior therapy or HCT regimen, or who have a low survival probability (e.g., refractory leukemia and\u002For undergoing 2nd HCT).\n* RECIPIENTS: Poor risk disease\u002Fdisease status including: Chronic myelogenous leukemia (CML) in blast crisis, acute myeloid leukemia (AML)\u002Facute lymphoblastic leukemia (ALL) beyond 2nd remission, multiple myeloma, and aplastic anemia.\n* RECIPIENTS: Females only: Pregnant or breastfeeding.\n* RECIPIENTS: Any other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures.\n* RECIPIENTS: Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility\u002Flogistics).",true,"18 Years","75 Years",{"count":56,"type":19},46,[58],"PHASE1","This phase Ib trial tests the safety, side effects, and how well cytomegalovirus (CMV)-modified vaccinia Ankara (MVA) Triplex vaccine works in enhancing CMV-specific immunity and preventing CMV viremia in patients undergoing haploidentical hematopoietic stem cell transplant. Haploidentical stem cell transplantation (haploHCT) has advanced to become the predominant procedure for patients lacking a matched donor. Compared to matched related donor transplants, the rate of significant CMV infection is higher in patients undergoing a haploHCT. Significant CMV infection is associated with an increased risk of complications and death. Vaccination is the main preventative approach to limit complications and death in immunocompromised patients at high risk of post-stem cell transplant infections. CMV-MVA Triplex vaccine, is a CMV vaccine based on the attenuated poxvirus, modified vaccinia Ankara (MVA), developed to enhance CMV-specific immunity in both healthy stem cell transplant donors and stem cell transplant patients to prevent significant CMV infection post-stem cell transplant. Giving CMV-MVA triplex vaccine may be safe, tolerable and\u002For effective in enhancing cytomegalovirus (CMV)-specific immunity and preventing CMV viremia in patients undergoing a haploHCT.",[61,62,63,64,65,66,29,67,68,69,70,71],"Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive","Acute Lymphoblastic Leukemia","Acute Myeloid Leukemia","Chronic Lymphocytic Leukemia","Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive","Hematopoietic and Lymphatic System Neoplasm","Lymphoblastic Lymphoma","Myelodysplastic Syndrome","Myelofibrosis","Myeloproliferative Neoplasm","Non-Hodgkin Lymphoma","RECRUITING",{"date":35,"type":36},{"date":33,"type":36},{"date":76,"type":19},"2028-05-30",{"name":78,"class":43},"City of Hope Medical Center",3,{"id":81,"slug":82,"hasResults":12,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":12,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":20,"phases":89,"briefSummary":91,"conditions":92,"keywords":94,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":104,"locationsCount":106},"100333226","phase-2-phase-ii-study-of-second--line-pembrolizumab-plus-gvd-for-relapsed-or-refractory-hodgkin-lymphoma-100333226","NCT03618550","Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma","Phase II Study of Second-line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma","Inclusion Criteria:\n\n* Histologic diagnosis of classical Hodgkin's lymphoma. Primary refractory or relapsed disease proven by biopsy at enrolling institution.\n* Stage I-III Hodgkin lymphoma (part 3)\n* Relapse or refractory disease following 1 line of multi-agent chemotherapy (not including pembro-GVD).\n* Eligible for HDT\u002FASCT\n* Achieved complete response (Deauville 3 or better) per clinical review following 2 cycles of pembro-GVD\n* Be willing and able to provide written informed consent\u002Fassent for the trial.\n* Be ≥ 18 years of age on day of signing informed consent.\n* Have measurable disease based on Lugano 2014 criteria\n* Have a performance status of 0 or 1 on the ECOG Performance Scale\n* Demonstrate adequate organ function as defined in table below\n* Demonstrate adequate organ function as defined in table below. Hematological\\*\n* Absolute neutrophil count (ANC) ≥1000 \u002FmcL\n* Platelets ≥50,000 \u002F mcL\n* Hemoglobin ≥8 g\u002FdL Renal\n* Serum creatinine OR ≤1.5 X upper limit of normal (ULN) OR\n* Measured or calculated creatinine clearance (eGFR can also be used in place of creatinine) ≥60 mL\u002Fmin for subject with creatinine levels \\> 1.5 X institutional ULN Hepatic\\*\n* Serum total bilirubin ≤ 1.5 X ULN OR ≤ 3 X ULN for subjects with liver metastases\n* AST (SGOT) and ALT (SGPT) ≤ 2.5 X ULN OR ≤ 5 X ULN for subjects with liver metastases Pulmonary\n* Hemoglobin-adjusted diffusing capacity for carbon monoxide ≥50% (If unadjusted DLCO is \\>\u002F= 50% then there is no need to calculate adjusted) Cardiac\n* Ejection fraction ≥45% Coagulation\n* International normalized ratio (INR) OR prothrombin time (PT), Activated partial thromboplastin time (aPTT): ≤ 1.5 × ULN unless participant is receiving anticoagulant therapy as long as PT or aPTT is within therapeutic range of intended use of anticoagulants\n\n  \\*Lab values for eligibility should be based upon labs prior to Cycle 1 treatment of Pembro-GVD.\n* Female subject of childbearing potential should have a negative urine or serum pregnancy within 2 weeks prior to receiving the first dose of study medication. On the day of planned treatment, if a blood pregnancy test has not been performed within the two week window, a stat pregnancy test (urine or blood) should be performed and the results reviewed before treatment is begun.\n* Female subjects of childbearing potential must be willing to use an adequate method of contraception (see details in section 11.4.3).\n* Male subjects of childbearing potential must agree to use an adequate method of contraception.(see details in section 11.4.3).\n* HIV-infected participants must have well-controlled HIV on ART, defined as:\n\n  * Participants on ART must have a CD4+ T-cell count ≥350 cells\u002Fmm3 at the time of screening\n  * Participants on ART must have achieved and maintained virologic suppression defined as confirmed HIV RNA level below 50 copies\u002FmL or the LLOQ (below the limit of detection) using the locally available assay at the time of screening and for at least 12 weeks before screening\n  * It is advised that participants must not have had any AIDS-defining opportunistic infections within the past 12 months.\n  * Participants on ART must have been on a stable regimen, without changes in drugs or dose modification, for at least 4 weeks before study entry (Day 1) and agree to continue ART throughout the study\n* Participants who have AEs due to previous anticancer therapies must have recovered to ≤Grade 1 or baseline. Participants with endocrine-related AEs who are adequately treated with hormone replacement or participants who have ≤Grade 2 neuropathy are eligible.\n\nExclusion Criteria:\n\n* Received more than 1 prior treatment (combined modality therapy represents 1 treatment) for Hodgkin Lymphoma\n* Known pregnancy or breast-feeding.\n\n  * Breast-feeding should be discontinued prior to treatment initiation.\n* Medical illness unrelated to Hodgkin's Lymphoma, which, in the opinion of the attending physician and\u002For principal investigator, makes participation in this study inappropriate.\n* Has received prior radiotherapy within 2 weeks of start of study treatment. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis.\n* Has known active central nervous system (CNS) metastases and\u002For carcinomatous meningitis.\n* Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.\n* Has known active HIV, Hepatitis B (e.g., Hepatitis B PCR positive) or Hepatitis C (e.g., HCV RNA \\[qualitative\\] is detected).\n* Has received a live vaccine or live-attenuated vaccine within 30 days prior to the first dose of study drug. Administration of killed vaccines is allowed.\n* Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis.\n* Has an active infection requiring systemic therapy.\n* Has not adequately recovered from major surgery or has ongoing surgical complications\n* Has undergone solid organ transplant at any time, or prior allogeneic hematopoietic stem cell transplantation within the last 5 years. (Subjects who have had an allogeneic hematopoietic transplant greater than 5 years ago are eligible as long as there are no symptoms of GVHD.)\n* Has a history or current evidence of any condition, therapy, or laboratory abnormality or other circumstance that might confound the results of the study, interfere with the participant's participation for the full duration of the study, such that it is not in the best interest of the participant to participate, in the opinion of the treating investigator\n* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.",{"count":88,"type":19},257,[90],"PHASE2","The purpose of this study is to test any good and bad effects of the study drug, pembrolizumab, in combination with GVD in the treatment of Hodgkin lymphoma.",[29,93],"Relapsed or Refractory Hodgkin Lymphoma",[95,96,97],"Pembrolizumab","GVD","18-160","2026-06-26",{"date":100,"type":36},"2026-06-29",{"date":102,"type":36},"2018-08-01",{"date":38,"type":19},{"name":105,"class":43},"Memorial Sloan Kettering Cancer Center",10,{"id":108,"slug":109,"hasResults":12,"nctId":110,"briefTitle":111,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":12,"sex":16,"minAge":53,"maxAge":54,"enrollmentInfo":113,"targetDuration":4,"studyType":20,"phases":115,"briefSummary":116,"conditions":117,"keywords":4,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":44},"100627130","phase-1-phase1-basket-trial-of-car70-engineered-il15-transduced-with-tgfbr2-knock-out-cord-blood-derived-nk-cells-for-relapsedrefractory-lymphoid-malignancies-100627130","NCT07444632","Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed\u002FRefractory Lymphoid Malignancies","Inclusion Criteria:\n\n1. 18-75 years of age.\n2. Diagnosis of relapsed B-NHL, HL, T-NHL, or B-ALL in refractory relapse, defined as:\n\n   * B-NHL: Failure of \\>\u002F= 1 salvage line and failure of or ineligibility for CAR-T.\n   * HL and T-NHL: Failure of \\>\u002F= 1 salvage line or prior SCT.\n   * ALL: Active disease (\\>5% of blasts or positive MRD at a level of \\>0.1% measured by multiparameter flow cytometry) after ≥ 2 two lines of therapy. Patients with B-ALL must have either failed of or be ineligible for CAR-T cell therapy. Patients who have mutations for which there are FDA approved targeted therapies (i.e., BCR-ABL) must also have received at least one of such agents.\n3. Expression of CD70 in the pre-enrollment sample \\>\u002F= 20% measured by immunohistochemistry or flow cytometry.\n4. Measurable disease, defined by \\>\u002F= 1 histologically confirmed hypermetabolic lesion on PET\u002FCT scan.\n5. ECOG PS ≤ 2 (Karnofsky ≥60%).\n6. Adequate blood counts (WBC \\>\u002F= 2K, HGB \\>\u002F= 8 g\u002FdL, platelets \\>\u002F= 50K).\n7. Creatinine clearance ≥ 30 ml\u002Fmin.\n8. ALT and\u002For AST ≤ 3 x ULN, and bilirubin and ALP ≤ 2 x ULN.\n9. FEV1, FVC and DLCOc ≥ 50%.\n10. LVEF ≥ 40%, without active arrythmias.\n11. If female of child-bearing potential, she must not be pregnant or breastfeeding and required to have a negative urine or serum pregnancy test prior to enrollment.\n12. For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.\n13. Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection still on treatment, they are eligible if they have an undetectable HCV viral load.\n14. Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression.\n15. Patients with a prior or concurrent malignancy whose natural history or treatment does not interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.\n16. Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better.\n17. The effects of CAR-NK cells on the developing human fetus are unknown. For this reason and because fludarabine and cyclophosphamide, as well as other therapeutic agents, used in this trial are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence, see Appendix 1) prior to study entry and for the duration of study participation. (Refer to Pregnancy Assessment Policy MD Anderson Institutional Policy # CLN1114).\n\n    * This includes all female patients, between the onset of menses (as early as 8 years of age) and 55 years unless the patient presents with an applicable exclusionary factor which may be one of the following:\n    * Postmenopausal (no menses in greater than or equal to 12 consecutive months).\n    * History of hysterectomy or bilateral salpingo-oophorectomy.\n    * Ovarian failure (Follicle Stimulating Hormone and Estradiol in menopausal range, who have received whole pelvic radiation therapy).\n    * History of bilateral tubal ligation or another surgical sterilization procedure.\n    * Approved methods of birth control (see Appendix 1) are as follows: Hormonal contraception (i.e. birth control pills, injection, implant, transdermal patch, vaginal ring), intrauterine device (IUD), tubal ligation or hysterectomy, subject\u002Fpartner post vasectomy, Implantable or injectable contraceptives, and condoms plus spermicide.\n\n    Not engaging in sexual activity for the total duration of the trial and the drug washout period is an acceptable practice; however periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.\n\n    • Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of CAR NK cell administration.\n18. Ability to understand and willingness to sign a written informed document.\n19. Agree to sign consent to the long-term follow-up protocol PA17-0483 to fulfill the institutional responsibilities to various regulatory agencies.\n\nExclusion Criteria:\n\n1. Lymphoma or ALL in CR with no measurable sites of disease.\n2. Major surgery \\\u003C4 weeks prior to first dose of study drug.\n3. Any other severe or uncontrolled disease or condition which mightincrease the risk associated with study participation.\n4. Any other malignancy known to be active, with the exception of treated cervical intraepithelial neoplasia and non-melanoma skincancer.\n5. Grade \\>\u002F= 3 non-hematologic toxicity from prior therapy that has notimproved to grade \\\u003C\u002F= 2.\n6. Active hepatitis B, either active carrier (HBsAg +) or viremic (HBV DNA \\>\u002F=10,000 copies\u002FmL, or \\>\u002F=2,000 IU\u002FmL), or hepatitis C (detectable viral load by HCV RNA PCR).\n7. Active infection requiring parenteral antibiotics.\n8. HIV infection.\n9. Treatment within prior 2 weeks with any anti-cancer agent,investigational or approved.\n10. Active CNS involvement (untreatedparenchymal brain metastasis or positive cytology of cerebrospinal fluid).\n11. Life expectancy \\\u003C\u002F= 6 months.\n12. Active and uncontrolled neurological disorder.\n13. Patients receiving systemic steroid therapy at time of enrollment (physiological replacement doses are allowed) or have received antithymocyte globulin or lymphocyte immune globulin within 14 days of enrollment or alemtuzumab within 28 days of enrollment.\n14. Patients receiving immunosuppressive therapy.\n15. Patients who are receiving any other investigational agents.\n16. Patients with psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.",{"count":114,"type":19},60,[58],"This is a phase 1 basket trial of TGFBR2 KO CAR27\u002FIL-15 NK cells after lymphodepleting chemotherapy for patients with R\u002FR B-NHL, HL, T-NHL or B-ALL.",[118,29],"Lymphoid","2026-06-23",{"date":98,"type":36},{"date":122,"type":36},"2026-05-28",{"date":124,"type":19},"2032-09-30",{"name":126,"class":43},"M.D. Anderson Cancer Center",{"id":128,"slug":129,"hasResults":12,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":133,"eligibilityCriteria":134,"healthyVolunteers":12,"sex":16,"minAge":135,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":20,"phases":138,"briefSummary":139,"conditions":140,"keywords":146,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":161},"100526622","phase-1-azd3470-as-monotherapy-or-in-combination-with-anticancer-agents-in-participants-with-haematologic-malignancies-100526622","NCT06137144","AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.","A Modular Phase I\u002FII, Open-label, Multicentre Study to Evaluate the Safety, Tolerability, and Efficacy of AZD3470, a PRMT5 Inhibitor, as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies","PRIMAVERA","Inclusion Criteria:\n\nCore Inclusion criteria:\n\n1. Adequate adult (ECOG) or adolescent (Karnofsy or Lanksy) Performance Score assessments\n2. Adequate organ and bone marrow function.\n\nModule 1 Cohort 1:\n\n1. Age:\n\n   1. Part A (dose escalation): aged ≥ 18 years at the time of signing the informed consent.\n   2. Part B (optimization): aged ≥ 12 years of age. Adolescent participants must weigh ≥ 40 kg.\n2. Histologically confirmed diagnosis of cHL based on WHO criteria\n3. Previous treatment with at least 2 prior lines of therapy for the treatment of cHL (including at least 2 cycles of BV and anti-PD1) and have documented r\u002Fr active disease requiring treatment.\n4. Participants must provide FFPE baseline tumour tissue.\n5. At least 1 radiographically measurable, and\u002For FDG-avid lymphoma lesion ( \\>1.5 cm for nodal lesion and \\>1 cm for extranodal lesion).\n\nModule 1 Cohort 2:\n\n1. Participants must be at least 50 years of age or older at study entry.\n2. Histologically confirmed diagnosis of cHL based on WHO criteria\n3. Ann Arbor stages III or IV.\n4. Participant must have previously received at least 4 cycles of SoC combination therapy with A-AVD, N-AVD, AVD, or ABVD (based on regional SOC, per investigator) as finite first-line induction therapy, and achieved at least a PR post-induction therapy.\n5. Participants must provide FFPE baseline tumour tissue.\n\nModule 1 Cohort 3:\n\n1. Participants must be aged ≥ 18 years at the time of signing the informed consent.\n2. Histologically confirmed diagnosis of PTCL NOS, systemic ALCL, or AITL based on WHO criteria.\n3. Participants must have received at least 1 prior line of therapy for the treatment of PTCL and have exhausted all available therapies with demonstrated clinical benefit. Participants with ALCL must have received prior BV treatment.\n4. Participants must provide FFPE baseline tumour tissue\n\n   a. Ability to provide an on-treatment biopsy (if the tumour is suitable for biopsy).\n5. At least 1 radiographically measurable, and\u002For FDG-avid lymphoma lesions (\\> 1.5 cm for nodal lesion and \\>1 cm for extranodal lesion).\n\nModule 2 Cohort 1:\n\n1. Participants must be aged ≥ 18 years at the time of signing the informed consent.\n2. Histologically confirmed diagnosis of cHL based on WHO criteria\n3. At least 1 radiographically measurable, and\u002For FDG-avid lymphoma lesions (\\> 1.5 cm for nodal lesion and \\>1 cm for extranodal lesion).\n4. Participant must have received at least 1 prior line of therapy for the treatment of cHL and have documented r\u002Fr active disease requiring treatment.\n5. Participants must provide FFPE baseline tumour tissue.\n\nExclusion Criteria:\n\nCore Exclusion criteria:\n\n1. Any significant laboratory finding or any severe and uncontrolled medical condition.\n2. Active CNS involvement by lymphoma, leptomeningeal disease, or spinal cord compression.\n3. Serologic active HBV or HCV infection.\n4. Known to have tested positive for HIV.\n5. Active gastrointestinal disease or other condition that will interfere with oral therapy.\n6. Any of the following ECG cardiac criteria: Mean resting QTcF \\> 470 msec, clinically important abnormalities in rhythm, conduction or morphology, and\u002For any factors that increase the risk of QTc prolongation or risk of arrhythmic events.\n7. Undergone any of the following procedures within 6 months prior to first dose:\n\n   1. Coronary artery bypass graft,\n   2. Percutaneous coronary intervention or heart valve replacement or repairment,\n   3. Vascular stent implantation (venous stent is eligible),\n   4. Acute coronary syndrome \u002F myocardial infarction,\n   5. Unstable or poorly controlled angina pectoris,\n   6. Ventricular arrhythmias requiring continuous therapy,\n   7. Uncontrolled atrial fibrillation,\n   8. Haemorrhagic or thrombotic stroke (including transient ischaemic attacks) or any other CNS bleeding.\n   9. Acute venous or atrial thromboembolic event (unless considered stable or adequately treated with at least 3months of therapeutic anticoagulation).\n8. Severe valvular heart disease.\n9. Congestive heart failure Grade II to Grade IV.\n10. Prior or current cardiomyopathy.\n11. Uncontrolled hypertension.\n12. History of significant haemoptysis or haemorrhage within4 weeks of the first dose of study treatment.\n13. Unresolved toxicities of Grade \\> 1 from prior anti cancer therapy (excluding peripheral neuropathy, vitiligo, alopecia and endocrine disorders that are controlled with replacement hormone therapy, and asymptomatic laboratory abnormalities), unless immune-mediated.\n14. History of another primary malignancy.\n15. Received the following anticancer therapies: anti-lymphoma therapy (within 21 days), radiation therapy(within 28 days), allo-HSCT (within 180 days), auto-HSCT\u002Fcellular therapy (within 60 days), or MAT2A or PRMT5 inhibitor\n16. Requires ongoing immunosuppressive therapy, including systemic corticosteroids.\n\nModule 2 Cohort 1:\n\n1. History of confirmed ILD, drug-induced ILD, radiation pneumonitis requiring steroid treatment or any evidence of clinically active ILD or pneumonitis.\n2. ≥Grade 3 immune-mediated AE while receiving prior checkpoint inhibitor immunotherapy, or any unresolved ≥Grade 2 immune-mediated AE.\n3. History of immune-mediated myocarditis or pericarditis.\n4. Experienced a toxicity that led to permanent discontinuation of prior immunotherapy.\n5. Active or prior documented pathologically confirmed autoimmune or inflammatory disorders\n6. Refractory to prior checkpoint inhibitor therapy (within 12 weeks of last dose)\n7. Eligible for allogeneic or autologous stem cell transplant.\n8. Received an allogeneic HSCT within 5 years of the first dose of study treatment; must not have active Graft-versus-host disease.\n9. Participants with a known hypersensitivity to pembrolizumab or any of the excipients of the product.","12 Years",{"count":137,"type":19},161,[58,90],"This study is designed to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy following oral administration of AZD3470 as a monotherapy, and in combination with other anticancer agents in participants with haematologic malignancies.",[141,71,29,142,143,144,145],"Lymphoma","Peripheral T-cell Lymphoma (PTCL)","PTCL-NOS","ALCL","AITL",[147,148,149,150,151],"Haematologic Malignancies","Hodgkin lymphoma","Peripheral T-cell lymphoma (PTCL)","Methylthioadenosine Phosphorylase (MTAP) deficient","Protein Arginine Methyltransferase 5 (PRMT5)",{"date":153,"type":36},"2026-06-24",{"date":155,"type":36},"2024-01-23",{"date":157,"type":19},"2029-05-03",{"name":159,"class":160},"AstraZeneca","INDUSTRY",37,{"id":163,"slug":164,"hasResults":12,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":4,"eligibilityCriteria":168,"healthyVolunteers":12,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":169,"targetDuration":4,"studyType":171,"phases":4,"briefSummary":172,"conditions":173,"keywords":4,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":184},"100516308","evaluating-the-impact-of-social-and-genetic-factors-on-outcomes-in-adolescent-and-young-adult-cancer-survivors-100516308","NCT06002828","Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors","Social Genomic Mechanisms of Health Disparities Among Adolescent and Young Adult (AYA) Survivors of Hodgkin and Non-Hodgkin Lymphoma","Inclusion Criteria:\n\n* Patient must be \\>= 18 years of age at the time of registration\n* Patient must have been between the ages of 15-39 at the time of their first primary cancer diagnosis of Hodgkin lymphoma or non-Hodgkin lymphoma (NHL)\n* Patient must have completed therapy (with a complete response, per clinician determination) at the time of registration\n* Patients last date of prior systemic therapy for first primary diagnosis for Hodgkin lymphoma or non-Hodgkin lymphoma must have been within one year prior to registration\n\n  * NOTE: Systemic therapy refers to all anti-cancer therapy, including but not limited to chemotherapy, intravenous (IV) or oral targeted medications, or radiation, and administered via a clinical trial or standard approach\n* Patient must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-3\n* Patient must be English speaking in order to be able to complete the required QOL forms on this study\n\n  * NOTE: Sites cannot translate the associated QOL forms\n* Patient must not be receiving active therapy for Hodgkin lymphoma or non-Hodgkin lymphoma\n* Patient must have internet access through computer, tablet, or smartphone\n* Patient must have email address\n* Patient must have the ability to understand and the willingness to sign a written informed consent document. Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and\u002For family member available will also be considered eligible",{"count":170,"type":19},2000,"OBSERVATIONAL","This study examines the impact of social and genetic factors on outcomes in adolescent and young adult (AYA) cancer survivors of Hodgkin or non-Hodgkin lymphoma. Compared to both older adult and childhood cancer patients, AYAs with cancer experience different diagnoses and specific biological, clinical, psychological and social factors that affect their risks for post-treatment morbidity and premature death. Collecting samples of blood samples and health and treatment information from cancer survivors of Hodgkin or non-Hodgkin lymphoma may help doctors identify conditions that increase the likelihood of AYAs getting sick and dying after treatment of cancer and better understand how to address the needs of adolescent and young adult cancer survivors.",[29,71],"2026-06-16",{"date":176,"type":36},"2026-06-18",{"date":178,"type":36},"2023-10-13",{"date":180,"type":19},"2030-02-01",{"name":182,"class":183},"ECOG-ACRIN Cancer Research Group","NETWORK",428,{"id":186,"slug":187,"hasResults":12,"nctId":188,"briefTitle":189,"officialTitle":189,"acronym":190,"eligibilityCriteria":191,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":192,"targetDuration":4,"studyType":171,"phases":4,"briefSummary":194,"conditions":195,"keywords":240,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":44},"100289631","familial-investigations-of-childhood-cancer-predisposition-100289631","NCT03050268","Familial Investigations of Childhood Cancer Predisposition","SJFAMILY","NOTE: This is a research study and is not meant to be a substitute for clinical genetic testing. Families may never receive results from the study or may receive results many years from the time they enroll. If you are interested in clinical testing please consider seeing a local genetic counselor or other genetics professional. If you have already had clinical genetic testing and meet eligibility criteria for this study as shown below, you may enroll regardless of the results of your clinical genetic testing.\n\nDEFINITION OF FAMILIAR CANCER FOR THIS PROTOCOL:\n\nIn this protocol, the definition of \"Familial Cancer\" is met if any of the following is present:\n\n* An individual with a history of cancer diagnosed under 26 years of age who has at least one first, second or third degree relative with a history of cancer diagnosed under 51 years of age; OR\n* An individual who has been diagnosed with more than one cancer, at least one of which was diagnosed under 26 years of age; OR\n* An individual with a clinical or molecular diagnosis of a known cancer predisposition syndrome; OR\n* An individual with a congenital cancer diagnosed before 6 months of age; OR\n* An individual with a rare pediatric cancer or tumor diagnosed before 26 years of age\n\nº Excluding human papilloma virus-associated cervical cancer and non-melanoma skin cancer occurring in adults.\n\nINCLUSION CRITERIA:\n\n* An individual who meets this protocol's definition of \"Familial Cancer,\" as above.\n* Biologic relatives of an individual meeting this protocol's definition of \"Familial Cancer,\" who are either affected or unaffected by cancer.\n\nEXCLUSION CRITERIA:\n\n* An inability or unwillingness of the research participant or his\u002Fher legally authorized representative (LAR) to provide written informed consent.\n* The participant has received allogeneic bone marrow transplantation and has NO pre-transplant germline (cancer-unaffected) DNA available AND is unwilling to provide a skin sample.",{"count":193,"type":19},1500,"NOTE: This is a research study and is not meant to be a substitute for clinical genetic testing. Families may never receive results from the study or may receive results many years from the time they enroll. If you are interested in clinical testing please consider seeing a local genetic counselor or other genetics professional. If you have already had clinical genetic testing and meet eligibility criteria for this study as shown in the Eligibility Section, you may enroll regardless of the results of your clinical genetic testing.\n\nWhile it is well recognized that hereditary factors contribute to the development of a subset of human cancers, the cause for many cancers remains unknown. The application of next generation sequencing (NGS) technologies has expanded knowledge in the field of hereditary cancer predisposition. Currently, more than 100 cancer predisposing genes have been identified, and it is now estimated that approximately 10% of all cancer patients have an underlying genetic predisposition.\n\nThe purpose of this protocol is to identify novel cancer predisposing genes and\u002For genetic variants. For this study, the investigators will establish a Data Registry linked to a Repository of biological samples. Health information, blood samples and occasionally leftover tumor samples will be collected from individuals with familial cancer. The investigators will use NGS approaches to find changes in genes that may be important in the development of familial cancer. The information gained from this study may provide new and better ways to diagnose and care for people with hereditary cancer.\n\nPRIMARY OBJECTIVE:\n\n* Establish a registry of families with clustering of cancer in which clinical data are linked to a repository of cryopreserved blood cells, germline DNA, and tumor tissues from the proband and other family members.\n\nSECONDARY OBJECTIVE:\n\n* Identify novel cancer predisposing genes and\u002For genetic variants in families with clustering of cancer for which the underlying genetic basis is unknown.",[196,197,198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,213,214,215,216,29,217,218,219,220,221,222,223,224,225,226,227,228,229,230,231,232,233,234,235,236,26,237,238,239],"Acute Leukemia","Adenomatous Polyposis","Adrenocortical Carcinoma","AML","BAP1 Tumor Predisposition Syndrome","Carney Complex","Choroid Plexus Carcinoma","Constitutional Mismatch Repair Deficiency Syndrome","Diamond-Blackfan Anemia","DICER1 Syndrome","Dyskeratosis Congenita","Emberger Syndrome","Familial Acute Myeloid Leukemia","Familial Adenomatous Polyposis","Fanconi Anemia","Familial Cancer","Familial Wilms Tumor","Familial Neuroblastoma","GIST","Hereditary Breast and Ovarian Cancer","Hereditary Paraganglioma-Pheochromocytoma Syndrome","Juvenile Polyposis","Li-Fraumeni Syndrome","Lynch Syndrome","MDS","Melanoma Syndrome","Multiple Endocrine Neoplasia Type 1","Multiple Endocrine Neoplasia Type 2","Neuroblastoma","Neurofibromatosis Type 1","Neurofibromatosis Type II","Nevoid Basal Cell Carcinoma Syndrome","Non Hodgkin Lymphoma","Noonan Syndrome and Other Rasopathy","Overgrowth Syndromes","Pancreatic Cancer","Peutz-Jeghers Syndrome","Pheochromocytoma\u002FParaganglioma","PTEN Hamartoma Tumor Syndrome","Retinoblastoma","Rhabdoid Tumor Predisposition Syndrome","Rothmund-Thomson Syndrome","Tuberous Sclerosis","Von Hippel-Lindau Disease",[241,242,243,244,245,246,247,248,249],"Familial cancer","Genetic predisposition","Heritable disease","Cancer risk","Genome analysis","Genetic modifiers","Next generation sequencing (NGS)","Genetic counseling","DNA","2026-06-15",{"date":252,"type":36},"2026-06-17",{"date":254,"type":36},"2017-04-06",{"date":256,"type":19},"2037-03-31",{"name":42,"class":43},{"id":259,"slug":260,"hasResults":12,"nctId":261,"briefTitle":262,"officialTitle":263,"acronym":4,"eligibilityCriteria":264,"healthyVolunteers":12,"sex":16,"minAge":265,"maxAge":53,"enrollmentInfo":266,"targetDuration":4,"studyType":20,"phases":268,"briefSummary":269,"conditions":270,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":272,"startDateStruct":274,"completionDateStruct":275,"leadSponsor":277,"locationsCount":44},"100643612","phase-1-pd-1-antibody-and-jak1-inhibitor-for-newly-diagnosed-pediatric-hodgikins-lympoma-100643612","NCT07641010","PD-1 Antibody and JAK1 Inhibitor for Newly Diagnosed Pediatric Hodgikin's Lympoma","A Prospective, Multicenter, Randomized Controlled Clinical Study of Camrelizumab in Combination With Ivarmacitinib as First-line Treatment for Pediatric Classical Hodgkin Lymphoma","Inclusion Criteria:\n\n1. Age 6-18 years, male or female;\n2. Histologically confirmed classic Hodgkin lymphoma;\n3. Newly diagnosed, previously untreated patients;\n4. Subjects must have at least one measurable lesion, defined as: a lymph node lesion with the longest diameter \\>1.5 cm on CT cross-sectional imaging; or an extranodal lesion with the longest diameter \\>1.0 cm;\n5. ECOG performance status (PS) 0-2;\n6. Life expectancy ≥3 months;\n7. All screening laboratory tests must be performed as required by the protocol and within 7 days prior to enrollment. The laboratory values obtained at screening must meet the following criteria:\n8. Hematology (without blood transfusion, G-CSF, or medication to correct abnormalities within 14 days prior to screening):\n\n   * Hemoglobin (Hb) ≥70 g\u002FL;\n   * Absolute neutrophil count (ANC) ≥0.5×10⁹\u002FL;\n   * Platelet count (PLT) ≥30×10⁹\u002FL;\n9. Biochemistry:\n\n   * Direct bilirubin (DBIL) \\\u003C2 × upper limit of normal (ULN);\n   * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤5 × ULN;\n   * Serum creatinine clearance ≥40 mL\u002Fmin;\n10. The patient or his\u002Fher legal guardian has signed the informed consent form (ICF) and voluntarily agrees to participate in this study.\n\nExclusion Criteria:\n\n1. Histopathologically confirmed nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL);\n2. Prior anti-tumor therapy for classic Hodgkin lymphoma (cHL);\n3. Patients with central nervous system (CNS) involvement by lymphoma;\n4. Inability to swallow oral medication, or any other factor affecting oral drug administration and absorption;\n5. Presence of any active, known, or suspected autoimmune disease (subjects who are in a stable condition and do not require systemic immunosuppressive therapy are permitted to enroll);\n6. Use of immunosuppressive agents, including systemic corticosteroids, within 14 days prior to study drug administration (use of ≤10 mg\u002Fday prednisone or equivalent is permitted);\n7. History of other malignancies within the past 5 years;\n8. Severe cardiac dysfunction with ejection fraction (EF) \\\u003C50%, or severe cardiac arrhythmia;\n9. Any arterial thromboembolic event within the past 6 months, including myocardial infarction, unstable angina, cerebrovascular accident, or transient ischemic attack;\n10. Active hepatitis B or hepatitis C infection;\n11. History of stroke or intracranial hemorrhage within the past 6 months;\n12. Known history of human immunodeficiency virus (HIV) positivity.","6 Years",{"count":267,"type":19},112,[58,90],"A prospective, multicenter, randomized controlled clinical study of camrelizumab in combination with ivarmacitinib as first-line treatment for pediatric classical Hodgkin lymphoma",[29],"2026-06-10",{"date":273,"type":36},"2026-06-11",{"date":33,"type":19},{"date":276,"type":19},"2030-09-30",{"name":278,"class":43},"Shanghai Jiao Tong University School of Medicine",{"id":280,"slug":281,"hasResults":12,"nctId":282,"briefTitle":283,"officialTitle":284,"acronym":4,"eligibilityCriteria":285,"healthyVolunteers":12,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":286,"targetDuration":4,"studyType":20,"phases":288,"briefSummary":289,"conditions":290,"keywords":4,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":291,"startDateStruct":293,"completionDateStruct":295,"leadSponsor":297,"locationsCount":299},"100338062","phase-1-nivolumab-with-ruxolitinib-in-relapsed-or-refractory-classical-hodgkin-lymphoma-100338062","NCT03681561","Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma","Phase I\u002FII Study of Nivolumab in Combination With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma","Inclusion Criteria:\n\n* Written informed consent and HIPAA authorization for release of personal health information. NOTE: HIPAA authorization may be included in the informed consent or obtained separately.\n* Age ≥ 18 years at the time of consent.\n* ECOG Performance Status of 0, 1 or 2.\n* Histologically confirmed diagnosis of classical Hodgkin lymphoma that is relapsed or refractory - historical biopsy at last relapse is acceptable. NOTE: a repeat biopsy is not required for Phase I if the historical biopsy was performed at the most recent relapse, without remission in between. A fresh biopsy is not required for Phase II.\n* Presence of radiographically measurable disease (defined as the presence one or more ≥ 1.5 cm lesions, as measured in the longest dimension by PET\u002FCT) within 4 weeks of study registration.\n* Prior therapy with check-point inhibitors (nivolumab, pembrolizumab, others) and subsequent progressive disease, stable disease, mixed response, or relapse\n* Failed at least one prior therapy\n* Prior cancer treatment must be completed at least 14 days prior to registration and the patient must have recovered from all reversible acute toxic effects of the regimen (other than alopecia) to ≤Grade 1 or baseline. Radiation therapy must be completed at least 7 days prior to registration.\n* Absolute Neutrophil Count ≥ 1000\u002FμL\n* Platelets ≥ 75,000\u002FμL (or ≥50,000\u002Fmm3 if known BM involvement)\n* Calculated creatinine clearance ≥ 40 cc\u002Fmin using the Cockcroft-Gault formula\n* Bilirubin ≤ 1.5 x upper limit of normal (ULN)\n* Aspartate aminotransferase (AST) ≤ 2.5 × ULN\n* Alanine aminotransferase (ALT) ≤ 2.5 × ULN\n* Females of childbearing potential must have a negative serum pregnancy test within 7 days prior to registration. NOTE: Females are considered of child bearing potential unless they are surgically sterile (have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are naturally postmenopausal for at least 12 consecutive months\n* Males who are sexually active with partners of child-bearing potential must be willing to abstain from heterosexual activity or adhere to contraception from the time of written consent until 7 months after treatment discontinuation.\n* Patient must provide voluntary written informed consent prior to the performance of any research related tests or procedures.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the mother is being treated on study).\n* Inability or unwillingness to swallow oral medication or any condition that precludes the administration and\u002For absorption of oral medications\n* A life-threatening illness, medical condition or organ system dysfunction, which in the investigator's opinion, could compromise the patient's safety, interfere with the metabolism of study drugs, or put the study outcomes at undue risk\n* Active central nervous system (CNS) involvement by lymphoma\n* Uncontrolled cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction or any class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification\n* Concomitant therapy with immunosuppressive agents, including systemic corticosteroids (doses ≤ 10 mg\u002Fday prednisone or equivalent are permitted).\n* Has a history of autoimmune disease now or in past 3 years such as hepatitis, nephritis, hyperthyroidism, interstitial lung disease or colitis except vitiligo or alopecia, hypothyroidism (eg, following Hashimoto syndrome) stable on hormone replacement or psoriasis not requiring systemic treatment\n* HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of registration are eligible for this trial.\n* Active Hepatitis B or C infection (defined as a positive Hepatitis B surface antigen (Ag) or detectable viral load by PCR). NOTES: Hepatitis B and C testing is required. Patients with positive Hepatitis B Ag may enroll if PCR is negative. Suppressive antiviral therapy should be considered for these patients as clinically indicated.\n* Currently active, clinically significant hepatic impairment Child-Pugh class B or C\n* Currently receiving a strong CYP3A4 Inhibitor (such as but not limited to boceprevir clarithromycin, conivaptan, grapefruit juice, indinavir, itraconazole, ketoconazole, lopinavir\u002Fritonavir, mibefradil, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, voriconazole) or Fluconazole \\>200 mg\u002Fday. Washout period of 1 week is required.\n* History of stroke or intracranial hemorrhage within 6 months of study registration",{"count":287,"type":19},54,[58,90],"This is a Phase I\u002FII, multicenter, open-label, dose escalation\u002Fdose-expansion study to evaluate the tolerability, safety, and the maximum tolerated dose (MTD) of ruxolitinib when given with fixed dose nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma (cHL).",[29],{"date":292,"type":36},"2026-06-12",{"date":294,"type":36},"2018-09-13",{"date":296,"type":19},"2027-07",{"name":298,"class":43},"Veronika Bachanova",6,{"id":301,"slug":302,"hasResults":12,"nctId":303,"briefTitle":304,"officialTitle":305,"acronym":4,"eligibilityCriteria":306,"healthyVolunteers":12,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":307,"targetDuration":4,"studyType":20,"phases":309,"briefSummary":310,"conditions":311,"keywords":4,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":315,"lastUpdatePostDateStruct":316,"startDateStruct":317,"completionDateStruct":319,"leadSponsor":321,"locationsCount":44},"100627624","phase-1-cd45be-hspc--cart-45-cells-100627624","NCT07451054","CD45BE-HSPC + CART-45 Cells","Phase 1 Study of Autologous Anti-CD45 CAR T Cells in Combination With CD45 Base Edited HSPCs in Patients With Relapsed or Refractory Hematologic Malignancies","Inclusion Criteria:\n\n1\\. Signed informed consent form 2. Male or females age ≥ 18 years 3. Disease-Specific Criteria\n\na. B-cell Non-Hodgkin Lymphoma (B-cell NHL)- including the following sub-types:\n\ni. Patients with any of the following large B-cell lymphoma diagnoses who meet the prior treatment criteria outlined below: Diffuse Large B-cell Lymphoma not otherwise specified (DLBCL NOS); Primary Cutaneous DLBCL; Primary Mediastinal (thymic) Large B-cell Lymphoma; ALK+ Anaplastic Large B-cell Lymphoma; High-Grade B-cell Lymphoma with MYC and BCL2 and\u002For BCL6 rearrangements (i.e., \"Double or Triple Hit\"); High-grade B-cell Lymphoma, NOS; T-cell Rich B-cell Lymphoma; Transformed Follicular Lymphoma; or any aggressive B-cell lymphoma arising from indolent lymphoma.\n\n1\\. Patients must have either failed\u002Frelapsed after, or be ineligible for, prior commercial CAR T cell therapy; AND 2. Relapsed\u002Frefractory disease after at least 2 prior lines of appropriate therapy.\n\nii. Follicular Lymphoma\n\n1. Patients must have either failed\u002Frelapsed after, or be ineligible for, prior commercial CAR T cell therapy; AND\n2. Relapsed\u002Frefractory disease after at least 2 prior lines of systemic therapy (not including a single agent monoclonal antibody therapy).\n\niii. Mantle Cell Lymphoma\n\n1. Patients must have either failed\u002Frelapsed after, or be ineligible for, prior commercial CAR T cell therapy; AND\n2. Relapsed\u002Frefractory disease after at least 2 prior lines of systemic therapy, including a Bruton tyrosine kinase (TKI) inhibitor. Single-agent monoclonal antibody therapy does not count towards prior lines of therapy.\n\n   iv. Marginal Zone Lymphoma- relapsed\u002Frefractory disease after at least 2 prior lines of appropriate therapy, including a Bruton tyrosine kinase (TKI) inhibitor. Note: Single-agent monoclonal antibody therapy does not count towards prior lines of therapy.\n\n   b. T-cell Non-Hodgkin Lymphoma (T-cell NHL)\n\n   i. Histologically or cytologically confirmed relapsed or refractory (r\u002Fr) mature aggressive T- and NK-cell neoplasms as defined in the 5th edition of the WHO Classification of Hematolymphoid tumors, which includes any of the following diagnoses:\n\n   • Peripheral T-cell Lymphoma, NOS (PTCL-NOS);\n\n   • Nodal T-cell Lymphomas with T Follicular Helper \\[TFH\\] Phenotype, including Follicular T cell Lymphoma, Angioimmunoblastic Lymphoma, or Anaplastic Large Cell Lymphoma (ALCL);\n\n   • ALK+ or ALK-, Enteropathy-Associated T-cell Lymphoma (EATL);\n\n   • Monomorphic Epitheliotropic Intestinal T-cell Lymphoma (MEITL);\n\n   • Extranodal NK\u002FT-cell Lymphoma;\n\n   • Primary Cutaneous T-cell Lymphoma (CTCL);\n\n   • Transformed Mycosis Fungoides (tMF) without blood involvement;\n\n   • Primary Cutaneous Aggressive Epidermotropic CD8+ Cytotoxic T-Cell Lymphoma;\n\n   • Subcutaneous Panniculitis-like T-cell Lymphoma.\n\n   ii. Must have received at least one prior line of systemic therapy for their lymphoma. Additional prior treatment provisions required for the following indications:\n\n1\\. Participants with Anaplastic Large Cell Lymphoma (ALCL) must have received prior Brentuximab vedotin, unless contraindicated.\n\n2\\. Participants with Subcutaneous Panniculitis-like T-cell Lymphoma or Transformed Mycosis Fungoides (tMF) must have received at least 2 prior lines of systemic therapy.\n\nc. Hodgkin Lymphoma (HL)\n\ni. Patients with histologically proven classical Hodgkin Lymphoma that is CD45 positive by IHC or flow cytometry by a CLIA certified laboratory; AND\n\nii. Relapsed\u002Frefractory disease after at least 2 prior lines of therapy which must include the following:\n\n1. Brentuximab vedotin and immune checkpoint inhibitors (unless contraindicated); AND\n2. Autologous stem cell transplant (unless patient has chemorefractory disease to salvage treatment) d. Large Cell Transformation of CLL (Richter's Transformation) i. Patients must be primary refractory or received at least 1 prior line of treatment for Richter's Transformation.\n\n4\\. Patients are appropriate candidates for autologous HSCT as per physician-investigator clinical discretion\n\n5\\. Patients with relapsed disease after prior allogeneic SCT must meet the following criteria:\n\na. Have no active GVHD and require no immunosuppression\n\nb. Are more than 6 months from transplant at the time of physician-investigator confirmation of eligibility\n\n6\\. Adequate organ function defined as:\n\n1. Serum creatinine ≤ 1.5x ULN or estimated creatinine clearance ≥ 35 mL\u002Fmin and not on dialysis\n2. ALT\u002FAST ≤ 3 x ULN\n3. Direct bilirubin ≤ 2.0 mg\u002Fdl; for patients with Gilbert's syndrome direct bilirubin must be ≤ 3.0 mg\u002Fdl\n4. Left Ventricular Ejection Fraction (LVEF) ≥ 40% confirmed by ECHO\u002FMUGA\n5. DLCO \\> 45% predicted value; adjusted for level of hemoglobin\n6. Must have minimum level of pulmonary reserve defined as ≤ Grade 1 dyspnea and pulse oxygen \\> 92% on room air 7. ECOG Performance Status 0-1\n\nExclusion Criteria:\n\n1. Active hepatitis B or hepatitis C infection\n2. Any active, uncontrolled infection.\n3. Class III\u002FIV cardiovascular disability according to the New York Heart Association Classification.\n4. Clinically apparent arrhythmia or arrhythmias that are not stable on medical management within two weeks of physician-investigator confirmation of eligibility.\n5. Severe, active co-morbidity that, in the opinion of the physician-investigator, would preclude participation in this study.\n6. Prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen.\n7. Active acute or chronic GVHD requiring systemic therapy.\n8. Dependence on systemic steroids or immunosuppressant medications. For additional details regarding use of steroid and immunosuppressant medications.\n9. Active CNS involvement. Patients with a history of CNS involvement that was successfully treated are eligible. A CNS evaluation is only required for eligibility if a subject is experiencing signs\u002Fsymptoms of CNS involvement.\n10. Patients with evidence of a circulating T-cell malignancy as measured by flow cytometry.\n11. History of allergy or hypersensitivity to study product excipients (human serum albumin, DMSO, and Dextran 40).\n12. Active autoimmune disease requiring systemic immunosuppressive treatment equivalent to ≥ 10mg of prednisone. Patients with autoimmune neurologic diseases (such as MS) will be excluded.\n13. Pregnant or nursing (lactating) patients. Participants of reproductive potential must agree to use acceptable birth control methods.",{"count":308,"type":19},42,[58],"This is a phase 1, open-label, dose-finding study to assess the safety, feasibility, pharmacokinetics and preliminary efficacy of autologous base edited anti-CD45 CAR T cells (referred to as \"CART-45 cells\") following an autologous transplant of CD45 base edited hematopoietic stem and progenitor cells (referred to as \"CD45BE-HSPC\") in patients with relapsed or refractory hematologic malignancies.",[312,313,314,29],"B-Cell Non-Hodgkin Lymphoma (NHL)","Richter's Transformation","T-Cell Non-Hodgkin Lymphoma","2026-06-08",{"date":271,"type":36},{"date":318,"type":19},"2026-07",{"date":320,"type":19},"2051-07",{"name":322,"class":43},"University of Pennsylvania",{"id":324,"slug":325,"hasResults":12,"nctId":326,"briefTitle":327,"officialTitle":327,"acronym":4,"eligibilityCriteria":328,"healthyVolunteers":12,"sex":16,"minAge":329,"maxAge":330,"enrollmentInfo":331,"targetDuration":4,"studyType":20,"phases":333,"briefSummary":334,"conditions":335,"keywords":336,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":315,"lastUpdatePostDateStruct":338,"startDateStruct":339,"completionDateStruct":340,"leadSponsor":342,"locationsCount":44},"100610035","feasibility-of-high-intensity-interval-training-in-survivors-of-childhood-adolescent-and-young-adult-hodgkin-lymphoma-100610035","NCT07222345","Feasibility of High Intensity Interval Training in Survivors of Childhood, Adolescent, and Young Adult Hodgkin Lymphoma","Inclusion Criteria:\n\n* Participant has been diagnosed with Hodgkin lymphoma between the ages of 10 to 25 years.\n* Participant is between the ages of \\>10 and \\\u003C25 years old the time of enrollment.\n* Participant has completed treatment (end of chemotherapy for those not receiving radiation therapy or end of radiation therapy) for Hodgkin lymphoma within 24 months prior to enrollment and recovered from any acute treatment-related adverse events.\n* Participant has been medically cleared to participate in physical activity.\n* Participant verbalizes understanding of directions for use of the web-based platform on the study provided iPad and heart rate monitor.\n\nExclusion Criteria:\n\n* Participant has evidence of relapsed disease.\n* Participant has a diagnosis of acute heart failure.\n* Participant reports currently participating in HIIT training or \\>420 minutes per week of moderate to vigorous physical activity.\n* Female participant who is currently pregnant.","10 Years","25 Years",{"count":332,"type":19},20,[22],"This pilot study evaluates the feasibility of a 12-week high intensity interval training (HIIT) program in survivors of childhood, adolescent, and young adult Hodgkin lymphoma within 24 months of completing treatment. Preliminary efficacy of the HIIT intervention for improved cardiorespiratory fitness, body composition, physical function, autonomic response to exercise, peripheral neuropathy, biological aging markers, and physical activity will also be evaluated.\n\nPrimary Objective:\n\nTo determine the feasibility of a 12-week high intensity interval training (HIIT) program in survivors of childhood, adolescent, and young adult Hodgkin lymphoma within 24 months of completing treatment.\n\nFeasibility will be assessed by:\n\n* Participation Rate: Number of eligible survivors approached who enroll.\n* Completion Rate: Number of scheduled HIIT sessions attended and number of enrolled participants who complete post-intervention testing.",[29],[337],"Childhood Cancer Survivor",{"date":271,"type":36},{"date":315,"type":36},{"date":341,"type":19},"2029-01",{"name":42,"class":43},{"id":344,"slug":345,"hasResults":12,"nctId":346,"briefTitle":347,"officialTitle":348,"acronym":349,"eligibilityCriteria":350,"healthyVolunteers":12,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":351,"targetDuration":4,"studyType":20,"phases":353,"briefSummary":354,"conditions":355,"keywords":361,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":315,"lastUpdatePostDateStruct":368,"startDateStruct":370,"completionDateStruct":372,"leadSponsor":374,"locationsCount":332},"100434327","phase-2-faecal-microbiota-transplantation-after-allogeneic-stem-cell-transplantation-100434327","NCT04935684","Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation","Faecal Microbiota Transplantation for Prevention of Graft-versus-host Sisease After Allogeneic Stem Cell Transplantation for Haematological Malignancies","TMF-Allo","Inclusion Criteria:\n\n* Patient aged 18 or over\n* Men and women\n* Patients affiliated with a social-security organization\n* Patients undergoing a myelo-ablative allo-HSCT for a controlled haematologic malignant disease, with peripheral stem cells, whatever the type of donor (except cord blood)\n* Signed and dated informed consent\n\nExclusion Criteria:\n\n* Status of tumor progression at the time of allo-HSCT\n* Inability to understand the protocol (linguistic barrier, cognitive difficulties)\n* Medical history of another progressive cancer or occurrence in the 3 previous years (excluding basal cell carcinoma)\n* Presence of a simultaneous serious and uncontrolled disease (severe cardiac, renal, hepatic or respiratory failure, severe sepsis)\n* Fecal incontinence\n* Participation in another clinical trial studying an allograft procedure including the type of graft, the type of immunosuppression, a preventive or a curative treatment of GvHD, or studying the effectiveness of a FMT in another indication.\n* Pregnant women\n* Patient under guardianship, curatorship or protection of justice",{"count":352,"type":19},150,[90],"The aim of this study is to assess the Fecal Microbiota Transplantation (FMT) efficacy in the prevention of allogeneic hematopoietic stem cell transplantation (allo-HSCT) complications and particularly Graft versus Host Disease (GvHD).\n\nThe hypothesis of this study is that allogeneic FMT may improve outcomes of these patients.",[356,357,358,29,359,360,64],"Acute Leukemia in Remission","Myelodysplastic Syndromes","Myeloproliferative Syndrome","Lymphoma, Non-Hodgkin","Myeloma",[362,363,364,365,366,367],"Allogeneic hematopoietic stem cell transplantation","Hematologic malignancies","Graft versus Host Disease","Intestinal microbiota","Intestinal dysbiosis","Fecal Microbiota Transplantation",{"date":369,"type":36},"2026-06-09",{"date":371,"type":36},"2022-12-20",{"date":373,"type":19},"2030-05",{"name":375,"class":43},"University Hospital, Clermont-Ferrand",{"id":377,"slug":378,"hasResults":12,"nctId":379,"briefTitle":380,"officialTitle":380,"acronym":4,"eligibilityCriteria":381,"healthyVolunteers":12,"sex":16,"minAge":53,"maxAge":54,"enrollmentInfo":382,"targetDuration":4,"studyType":20,"phases":383,"briefSummary":384,"conditions":385,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":387,"lastUpdatePostDateStruct":388,"startDateStruct":389,"completionDateStruct":391,"leadSponsor":393,"locationsCount":44},"100605588","phase-2-phase-2-trial-of-cd70car-nk-cells-for-patients-with-primary-refractory-or-early-relapsed-diffuse-large-b-cell-lymphoma-and-hodgkin-lymphoma-100605588","NCT07164469","Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma","Inclusion Criteria:\n\n1. 18-75 years of age.\n2. Diagnosis of cHL or DLBCL that is either:\n\n   * Primary refractory, defined as not having achieved a CR with frontline therapy or having relapsed within 3 months.\n   * Early relapsed (≤ 12 months) after achieving a CR to frontline therapy.\n3. Tumor biopsy positive for CD70 \\>\u002F= 10% by immunohistochemistry or flow cytometry.\n4. Measurable disease, defined by one or more histologically confirmed hypermetabolic lesion on PET\u002FCT scan.\n5. ECOG PS ≤ 2 (Karnofsky ≥60%).\n6. Adequate blood counts (WBC \\> 2K, HGB \\> 8 g\u002FdL, platelets \\> 50K).\n7. Creatinine clearance ≥ 30 ml\u002Fmin.\n8. ALT and\u002For AST ≤ 3 x ULN, and bilirubin and ALP ≤ 2 x ULN.\n9. FEV1, FVC and DLCOc ≥ 50%.\n10. LVEF ≥40%, without active arrythmias.\n11. If female of child-bearing potential, she must not be pregnant or breastfeeding and is required to have a negative urine or serum pregnancy test prior to enrollment.\n12. For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.\n13. Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.\n14. Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression.\n15. Patients with a prior or concurrent malignancy whose natural history or treatment does not interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.\n16. Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification.\n\n    To be eligible for this trial, patients should be class 2B or better.\n17. The effects of CAR-NK cells on the developing human fetus are unknown. For this reason and because fludarabine and cyclophosphamide, as well as other therapeutic agents used in this trial are known to be teratogenic, women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. (Refer to Pregnancy Assessment Policy MD Anderson Institutional Policy # CLN1114).\n\n    * This includes all female patients, between the onset of menses (as early as 8 years of age) and 55 years unless the patient presents with an applicable exclusionary factor which may be one of the following: Postmenopausal (no menses in greater than or equal to 12 consecutive months). History of hysterectomy or bilateral salpingo-oophorectomy. Ovarian failure (Follicle Stimulating Hormone and Estradiol in menopausal range, who have received Whole Pelvic Radiation Therapy). History of bilateral tubal ligation or another surgical sterilization procedure.\n    * Approved methods of birth control are as follows: Hormonal contraception (i.e. birth control pills, injection, implant, transdermal patch, vaginal ring), Intrauterine device (IUD), Tubal Ligation or hysterectomy, Subject\u002FPartner post vasectomy, Implantable or injectable contraceptives, and condoms plus spermicide. Not engaging in sexual activity for the total duration of the trial and the drug washout period is an acceptable practice; however periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.\n    * Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of CAR NK cell administration.\n18. Ability to understand and the willingness to sign a written informed consent document.\n19. Agree to sign consent to the long-term follow-up protocol PA17-0843 to fulfill the institutional responsibilities to various regulatory agencies.\n\nExclusion Criteria:\n\n1. Lymphoma in CR with no measurable sites of disease.\n2. Major surgery \\\u003C4 weeks prior to first dose of study drug.\n3. Any other severe or uncontrolled disease or condition which might increase the risk associated with study participation.\n4. Any other malignancy known to be active, with the exception of treated cervical intra-epithelial neoplasia and non-melanoma skin cancer.\n5. Grade \\>\u002F= 3 non-hematologic toxicity from prior therapy that has not improved to grade \\\u003C\u002F= 2.\n6. Active hepatitis B, either active carrier (HBsAg +) or viremic (HBV DNA\n\n   \\>\u002F=10,000 copies\u002FmL, or \\>\u002F=2,000 IU\u002FmL), or hepatitis C (detectable viral load by HCV RNA PCR).\n7. Active infection requiring parenteral antibiotics.\n8. HIV infection.\n9. Treatment within prior 2 weeks with any anti-cancer agent, investigational or approved.\n10. Active central nervous system (CNS) involvement (untreatedparenchymal brain metastasis or positive cytology of cerebrospinal fluid).\n11. Life expectancy \\\u003C\u002F= 6 months.\n12. Active and uncontrolled neurological disorder.\n13. Patients receiving systemic steroid therapy at time of enrollment (physiological replacement doses are allowed) or have received antithymocyte globulin or lymphocyte immune globulin within 14 days of enrollment or alemtuzumab within 28 days of enrollment.\n14. Patients receiving immunosuppressive therapy.",{"count":18,"type":19},[90],"This clinical research study is to learn if CD70.CAR NK cell therapy can help to control early relapsed or primary refractory DLBCL and cHL.",[386,29],"Large B-cell Lymphoma","2026-06-04",{"date":315,"type":36},{"date":390,"type":19},"2026-06-28",{"date":392,"type":19},"2033-09-30",{"name":126,"class":43},{"id":395,"slug":396,"hasResults":12,"nctId":397,"briefTitle":398,"officialTitle":398,"acronym":4,"eligibilityCriteria":399,"healthyVolunteers":12,"sex":16,"minAge":135,"maxAge":400,"enrollmentInfo":401,"targetDuration":4,"studyType":20,"phases":403,"briefSummary":404,"conditions":405,"keywords":4,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":387,"lastUpdatePostDateStruct":415,"startDateStruct":416,"completionDateStruct":418,"leadSponsor":420,"locationsCount":44},"100446362","phase-1-phase-iii-study-of-car70--engineered-il15-transduced-cord-blood-derived-nk-cells-in-conjunction-with-lymphodepleting-chemotherapy-for-the-management-of-relapserefractory-hematological-malignances-100446362","NCT05092451","Phase I\u002FII Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse\u002FRefractory Hematological Malignances","Inclusion criteria:\n\n1. Patients with hematological malignances with an expression of CD70 in the pre-enrollment tumor sample ≥ 10% measured by immunohistochemistry or flow cytometry.\n2. Patients must meet diseases specific eligibility criteria (see below)\n3. Patients at least 1 week from last cytotoxic chemotherapy at the time of starting lymphodepleting chemotherapy, except for Hydroxyurea which is allowed for peripheral blood count control in AML, CML, and MDS patients until the day prior to administration of lymphodepleting chemotherapy. Patients may continue tyrosine kinase inhibitors or other targeted therapies until up to three days prior to administration of lymphodepleting chemotherapy.\n4. Localized radiotherapy to one or more disease sites is allowed prior the infusion provided that there are additional disease sites that are not irradiated to assess response\n5. Karnofsky Performance Scale \\> 50% for patients who are \\>16 years old or Lansky score ≥50% for patients who are ≤16 years of age.\n6. Adequate organ function:\n\n   1. Renal: Serum creatinine \\\u003C\u002F= 2x ULN or estimated Glomerular Filtration Rate \\>\u002F= 30 ml\u002Fmin\u002F1.73 m2\n   2. Hepatic: ALT\u002FAST \\\u003C\u002F= 3 x ULN or \\\u003C\u002F= 5 x ULN if documented liver metastases, Total bilirubin \\\u003C\u002F2xULN, except in subjects with Gilbert's Syndrome in whom total bilirubin must be \\\u003C\u002F= 3 x.ULN. No history of liver cirrhosis. No ascites.\n   3. Cardiac: Cardiac ejection fraction \\>\u002F= 40%, no clinically significant pericardial effusion as determined by an ECHO, and no uncontrolled arrhythmias or symptomatic cardiac disease.\n   4. Pulmonary: No clinically significant pleural effusion (per PI discretion), baseline oxygen saturation \\> 92% on room air and adequate pulmonary function with FEV1, FVC and DLCO (corrected for Hgb) \\>50%.\n7. Able to provide written informed consent.\n8. 12-80 years of age.\n9. Weight ≥40 kg\n10. All participants who are able to have children must practice effective birth control while on study and up to 3 months post completion of study therapy. Acceptable forms of birth control for female patients include: hormonal birth control, intrauterine device, diaphragm with spermicide, condom with spermicide, or abstinence, for the length of the study. If the participant is a female and becomes pregnant or suspects pregnancy, she must immediately notify her doctor. If the participant becomes pregnant during this study, she will be taken off this study. Men who are able to have children must use effective birth control while on the study. If the male participant fathers a child or suspects that he has fathered a child while on the study, he must immediately notify his doctor.\n11. Signed consent to long-term follow-up protocol PA17-0483 to fulfill the institutional responsibilities to various regulatory agencies.\n12. Are willing and able to provide informed consent, as appropriate (either directly or through a legally authorized representative \\[LAR\\])\n\nExclusion criteria:\n\n1. Positive beta HCG in female of child-bearing potential defined as not postmenopausal for 24 months or no previous surgical sterilization or lactating females.\n2. Presence of clinically significant Grade 3 or greater toxicity from the previous treatment, as determined by PI.\n3. Presence of uncontrolled fungal, bacterial, viral, or other infection not responding to appropriate therapy.\n4. HIV with detectable viral load\n5. Presence of active neurological disorder(s).\n6. Active autoimmune disease within 12 months of enrollment\n7. Amyloidosis or POEMS syndrome\n8. Active cerebral or meningeal involvement by the malignancy\n9. Active (defined as requiring therapy) acute or chronic GVHD\n10. Any other malignancy known to be active, except for treated cervical intra-epithelial neoplasia and non-melanoma skin cancer.\n11. Presence of any other serious medical condition that may endanger the patient at investigator discretion.\n12. Major surgery \\\u003C4 weeks prior to first dose of the preparatory chemotherapy\n13. Allogeneic SCT or DLI \\\u003C12 weeks prior to first dose of preparatory chemotherapy\n14. Concomitant use of other investigational agents.\n15. Concomitant use of other anti-cancer agents.\n16. Patients receiving systemic steroid therapy at time of NK cell infusion (physiological substitutive doses are allowed), or have received antithymocyte globulin or lymphocyte immune globulin within 14 days of enrollment or alemtuzumab within 28 days of enrollment.\n17. Patients receiving immunosuppressive therapy","80 Years",{"count":402,"type":19},80,[58,90],"The goal of this clinical research study is to learn about the safety of giving immune cells called natural killer (NK) cells with chemotherapy to patients with leukemia, lymphoma, or multiple myeloma.\n\nImmune system cells (such as NK cells) are made by the body to attack foreign or cancerous cells. Researchers think that NK cells you receive from a donor may react against cancer cells in your body, which may help to control the disease.",[406,407,408,409,410,29,411,412,413,414],"B-Cell Lymphoma","Myelodysplastic Syndromes (MDS)","Acute Myeloid Leukemia (AML)","Multiple Myeloma","Plasma Cell Leukemia","T-cell Non-Hodgkin's Lymphoma\u002F T-cell Acute Lymphoblastic Leukmeia","Myelodysplastic Syndrome \u002F Chronic Myelomonocytic Leukemia","Blastic Transformation of Chronic Myeloid Leukemia","Germ Cell Tumors",{"date":315,"type":36},{"date":417,"type":36},"2022-11-01",{"date":419,"type":19},"2026-08-31",{"name":126,"class":43},{"id":422,"slug":423,"hasResults":12,"nctId":424,"briefTitle":425,"officialTitle":426,"acronym":4,"eligibilityCriteria":427,"healthyVolunteers":12,"sex":16,"minAge":428,"maxAge":429,"enrollmentInfo":430,"targetDuration":4,"studyType":171,"phases":4,"briefSummary":432,"conditions":433,"keywords":447,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":451,"lastUpdatePostDateStruct":452,"startDateStruct":453,"completionDateStruct":455,"leadSponsor":457,"locationsCount":459},"100526212","pharmacokinetic-study-of-venetoclax-tablets-crushed-and-dissolved-into-a-solution-100526212","NCT06131801","Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution","A Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution in Children and Young Adults With Hematologic Malignancies","Inclusion Criteria:\n\n* Age: Patients must be \\\u003C39 years of age at time of study enrollment\n* Diagnosis: Patients may have a diagnosis of any hematologic malignancy\n* Central access: Patients must have an existing venous or arterial access line for PK blood draws\n* Weight requirement: Patients must weigh at least 5.5 kg at the time of enrollment\n* Venetoclax: Patients must be receiving any dose of venetoclax given as a solution made from crushed tablets by mouth (PO) or via nasogastric (NG), or G-tube as prescribed by their treating oncologist.\n* Concurrent chemotherapy medications: Patients may receive venetoclax as a single agent or in combination with any other chemotherapeutic agents.\n\nExclusion Criteria:\n\n* Pregnant women are excluded from this study because venetoclax has the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with venetoclax, breastfeeding should be discontinued if the mother is treated with venetoclax.\n* Males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method while on study treatment and for six months following completion.","0 Years","38 Years",{"count":431,"type":19},30,"The use of venetoclax-based therapies for pediatric patients with relapsed or refractory malignancies is increasingly common outside of the clinical trial setting. For patients who cannot swallow tablets, it is common to crush the tablets and dissolve them in liquid to create a solution. However, no PK data exists in adults or children using crushed tablets dissolved in liquid in this manner, and as a result, the venetoclax exposure with this solution is unknown.\n\nPrimary Objectives\n\n• To determine the pharmacokinetics of venetoclax when commercially available tablets are crushed and dissolved into a solution\n\nSecondary Objectives\n\n* To evaluate the safety of crushed venetoclax tablets administered as an oral solution\n* To determine the pharmacokinetics of venetoclax solution in patients receiving concomitant strong and moderate CYP3A inhibitors\n* To determine potential pharmacokinetic differences based on route of venetoclax solution administration (ie. PO vs NG tube vs G-tube)\n* To determine the concentration of venetoclax in cerebral spinal fluid when administered as an oral solution",[434,435,141,436,16,437,199,438,439,70,228,29,440,441,442,443,444,445,446],"Hematologic Malignancy","Leukemia","Acute Lymphocytic Leukemia","Acute Myelogenous Leukemia","Chronic Myelogenous Leukemia","CML","Diffuse Large B Cell Lymphoma","Follicular Lymphoma","Burkitt Lymphoma","T-cell Lymphoma","B Cell Lymphoma","Peripheral T Cell Lymphoma","Cutaneous B-Cell Lymphoma",[448,449,450],"Venetoclax","Pediatric AML","Pediatric Relapsed\u002FRefractory AML","2026-06-02",{"date":387,"type":36},{"date":454,"type":36},"2023-11-15",{"date":456,"type":19},"2027-12-01",{"name":458,"class":43},"Children's Hospital Medical Center, Cincinnati",5,{"id":461,"slug":462,"hasResults":12,"nctId":463,"briefTitle":464,"officialTitle":465,"acronym":4,"eligibilityCriteria":466,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":467,"targetDuration":4,"studyType":171,"phases":4,"briefSummary":469,"conditions":470,"keywords":4,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":451,"lastUpdatePostDateStruct":487,"startDateStruct":488,"completionDateStruct":490,"leadSponsor":492,"locationsCount":494},"100159702","a-multicenter-access-and-distribution-protocol-for-unlicensed-cryopreserved-cord-blood-units-cbus-100159702","NCT01351545","A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)","A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications","Inclusion Criteria:\n\n* Disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment\n* Signed informed consent (and signed assent, if applicable) obtained prior to study enrollment\n* Pediatric and adult patients of any age\n\nExclusion Criteria:\n\n* Patients who are receiving only licensed CBUs\n* Cord blood transplant recipients at international transplant centers\n* Patients who are enrolled on another IND protocol to access the unlicensed CBU(s)\n* Patients whose selected unlicensed CBU(s) will be more than minimally manipulated",{"count":468,"type":19},99999,"This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.",[471,472,473,474,475,476,477,478,479,480,29,481,482,483,484,485,486],"Hematologic Malignancies","Inherited Disorders of Metabolism","Inherited Abnormalities of Platelets","Histiocytic Disorders","Acute Myelogenous Leukemia (AML or ANLL)","Acute Lymphoblastic Leukemia (ALL)","Other Acute Leukemia","Chronic Myelogenous Leukemia (CML)","Myelodysplastic (MDS) \u002F Myeloproliferative (MPN) Diseases","Other Leukemia","Non-hodgkin Lymphoma","Multiple Myeloma\u002F Plasma Cell Disorder (PCD)","Inherited Abnormalities of Erythrocyte Differentiation or Function","Disorders of the Immune System","Autoimmune Diseases","Severe Aplastic Anemia",{"date":387,"type":36},{"date":489,"type":4},"2011-10",{"date":491,"type":19},"2041-10",{"name":493,"class":183},"Center for International Blood and Marrow Transplant Research",142,{"id":496,"slug":497,"hasResults":12,"nctId":498,"briefTitle":499,"officialTitle":500,"acronym":501,"eligibilityCriteria":502,"healthyVolunteers":12,"sex":16,"minAge":503,"maxAge":504,"enrollmentInfo":505,"targetDuration":4,"studyType":20,"phases":507,"briefSummary":509,"conditions":510,"keywords":511,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":515,"lastUpdatePostDateStruct":516,"startDateStruct":517,"completionDateStruct":519,"leadSponsor":521,"locationsCount":523},"100415129","phase-3-brentuximab-vedotin-in-early-stage-hodgkin-lymphoma-100415129","NCT04685616","Brentuximab Vedotin in Early Stage Hodgkin Lymphoma","A Randomised Phase III Trial With a PET Response Adapted Design Comparing ABVD +\u002F- ISRT With A2VD +\u002F- ISRT in Patients With Previously Untreated Stage IA\u002FIIA Hodgkin Lymphoma","RADAR","Inclusion Criteria:\n\n* Males and females aged 16-69 years (inclusive) (age range is 18-69 in US and EU)\n* Histologically confirmed classical Hodgkin lymphoma\n* Stage I or II supradiaphragmatic disease with no mediastinal bulk disease (defined as greater than a third of the transthoracic diameter at any level of thoracic vertebra as determined by CT) or B symptoms. Bulky disease at other sites is acceptable. Extranodal disease (single extranodal site (stage I) or contiguous nodal extension (stage II)) is acceptable.\n* ECOG performance status 0-2.\n* No previous treatment for Hodgkin lymphoma\n* Fit to receive anthracycline-based chemotherapy (patients with a history of ischaemic heart disease or hypertension should have a left ventricular ejection fraction of ≥50%)\n* Creatinine clearance (measured or calculated \\>40ml\u002Fmin\n* Total bilirubin \\\u003C1.5 x upper limit of normal, unless attributable to disease or known Gilbert's syndrome\n* ALT or AST \\\u003C 2 x upper limit of normal\n* Adequate bone marrow function with neutrophils ≥1.0x10\\^9\u002Fl and platelets ≥100x10\\^9\u002Fl\n* Haemoglobin ≥8g\u002FdL\n* Willing and able to comply with the requirements of the protocol, including contraceptive advice, where applicable\n* Written informed consent\n\nExclusion Criteria:\n\n* Previous treatment for Hodgkin lymphoma, excluding short courses of oral corticosteroids at a dose of 100mg prednisolone (or equivalent) for up to 7 days\n* Infradiaphragmatic disease\n* Nodular lymphocyte predominant Hodgkin lymphoma\n* Absence of FDG-avid lesions on baseline PET scan\n* Age 70 years or over or age 15 years or under\n* Other cancer diagnosed with the last 5 years. Patients with completely excised carcinoma in situ of any type and basal or squamous cell carcinoma of the skin are not excluded\n* Recurrent or persistent other cancer within last 5 years irrespective of date of initial diagnosis\n* Pre-existing grade ≥1 sensory or motor neuropathy from any cause\n* History of or current progressive multi-focal leukoencephalopathy or other chronic condition of the brain\n* Symptomatic neurologic disease compromising normal activities of daily living or requiring medications\n* Infection with HIV, hepatitis C or active hepatitis B infection (surface antigen or DNA positive)\n* Any active systemic viral, bacterial or fungal infection requiring systemic antibiotics, antivirals or antifungals within 2 weeks prior to first trial drug dose\n* Receiving or recently treated with any other investigational agent (within 4 weeks of trial entry)\n* Pregnant or breastfeeding women\n* Known hypersensitivity to recombinant proteins, murine proteins, or to any excipient contained in the drug formulation of brentuximab vedotin or any component of ABVD\n* Known history of any cardiovascular or respiratory conditions that would preclude anthracycline or bleomycin administration\n* Other significant medical or psychiatric comorbidity that in the opinion of the investigator would make administration of ABVD or A2VD hazardous","16 Years","69 Years",{"count":506,"type":19},1042,[508],"PHASE3","RADAR is a multicentre, international, randomised, open-label phase III clinical trial composed of 2 trials running in parallel. Trial 1 will be led and sponsored by University College London (UCL) and conducted in Europe and Australia\u002FNew Zealand. Trial 2 will be led by the Canadian Cancer Trials Group (CCTG) and conducted in North America, with CCTG the regulatory sponsor in Canada, and University of Miami the regulatory sponsor and IND holder in the US. Datasets from Trial 1 and Trial 2 will be combined to achieve the total sample size. Data analysis will be performed by UCL and therefore UCL is responsible for the clinicaltrials.gov entry.\n\nEligible patients will be randomised to receive either ABVD or A2VD chemotherapy.\n\nAn interim PET-CT scan will be performed after 2 cycles of treatment, which will be used to adapt subsequent treatment. Patients will receive a total of 3-4 cycles of chemotherapy and may also receive involved site radiotherapy as consolidation.\n\nPatients will be followed up for a minimum of 5 years after treatment.",[29],[512,513,514],"PET-response adapted","Stage IA\u002FIIA Hodgkin lymphoma","Brentuximab vedotin","2026-05-29",{"date":451,"type":36},{"date":518,"type":36},"2022-04-14",{"date":520,"type":19},"2032-09",{"name":522,"class":43},"University College, London",71,{"id":525,"slug":526,"hasResults":12,"nctId":527,"briefTitle":528,"officialTitle":529,"acronym":530,"eligibilityCriteria":531,"healthyVolunteers":12,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":532,"targetDuration":4,"studyType":20,"phases":534,"briefSummary":535,"conditions":536,"keywords":4,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":538,"startDateStruct":540,"completionDateStruct":542,"leadSponsor":544,"locationsCount":44},"100639077","phase-1-a-phase-i-study-of-jlm019-injection-100639077","NCT07623850","A Phase I Study of JLM019 Injection","A Phase I Study to Evaluate the Safety and Tolerability of JLM019 Injection in Patients With Advanced Malignancies","JLM019","Inclusion Criteria:\n\n1. Eighteen years of age or older;\n2. Patients with histopathologically or cytologically confirmed advanced solid tumors (AST) or relapsed\u002Frefractory (r\u002Fr) Hodgkin's\u002FNon-Hodgkin's lymphomas (HL\u002FNHL, including transformed lymphomas):\n\n   * AST subtypes include but are not limited: colorectal cancer (CRC), head and neck squamous cell carcinoma (HNSCC), hepatocellular carcinoma (HCC), non-small cell lung cancer (NSCLC), gastric cancer (GC), ovarian cancer (OV), renal cell carcinoma (RCC), melanoma, biliary tract cancer (BTC), alveolar soft part sarcoma (ASPS), etc.\n   * HL\u002FNHL subtypes include but are not limited: classical Hodgkin lymphoma (cHL), diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma (HGBL), mantle cell lymphoma (MCL), etc.\n3. Measurable disease as defined as:\n\n   * AST: At least one tumor lesion ≥ 10 mm in the longest diameter as assessed by computed tomography (CT);\n   * HL\u002FNHL: Fluorodeoxyglucose (FDG) avid disease by positron emission tomography (PET) and ≥ 1 lesion \\> 15 mm in the longest diameter by \\> 10 mm in the short axis, as assessed by CT;\n4. Patients with the following molecular profiles will be prioritized for enrollment:\n\n   * High tumor T-cell infiltration (e.g., elevated T-cell GEP score);\n   * TMB \\> 10 mut\u002FMb、MSI-H\u002FdMMR status or POLE\u002FPOLD1 mutations. Absence of β2M and JAK1\u002FJAK2 loss-of-function mutations.\n5. Submission of tumor biopsy representative of the current disease, which may consist of any of the following:\n\n   * Archived formalin-fixed paraffin-embedded (FFPE) tissue block;\n   * At least 15-20 slides of tumor tissue from an FFPE block suitable for immunohistochemistry (IHC), including ≥ 10 % tumor content per section with ≥ 20 mm2 of evaluable tissue which may include ≤ 50 % tumor adjacent tissue;\n   * A fresh tumor biopsy obtained by surgical excision or core needle procedure prior to the first dose of JLM019 Injection;\n6. For patients with accessible tumors, willingness to undergo on-study biopsy as scheduled in the protocol;\n7. Eastern Cooperative Oncology Group (ECOG) performance status grade 0\\~1;\n8. Life expectancy ≥ 3 months estimated by the Investigator;\n9. Recovery to Grade ≤ 1 for any non-laboratory toxicity resulting from previous anticancer therapy prior to the first dose of investigational product (except alopecia, hearing loss, Grade ≤ 2 neuropathy, or endocrinopathy managed with replacement therapy);\n10. Adequate baseline hematologic, renal, hepatic, and cardiac function as defined by:\n\n    * Lymphocyte ≥ 0.5 × 109\u002FL；\n    * ANC ≥ 1.5 × 109\u002FL;\n    * Platelet count (PLT) ≥ 100 × 109\u002FL;\n    * Hemoglobin (HGB)≥ 90 g\u002FL (no packed red blood cell transfusion within the prior 2 weeks);\n    * Serum total bilirubin (TBIL) ≤ 1.5 × upper limit of normal (ULN) or ≤ 3 × ULN for patients with Gilbert's disease;\n    * Estimated glomerular filtration rate (eGFR) ≥ 30 mL\u002Fmin\u002F1.73 m2, as calculated by the Modification of Diet in Renal Disease (MDRD) formula;\n    * ALT and AST ≤ 2.5 × ULN (≤ 5 × ULN if there is evidence of hepatic involvement by malignant disease);\n    * International normalized ratio (INR) or prothrombin time (PT) and activated partial thromboplastin time (aPTT) ≤1.5 × ULN unless the patient is receiving anticoagulant therapy in which PT or aPTT is within therapeutic range of intended use of anticoagulants;\n    * High sensitivity cardiac troponin I (hs-cTnI) and N-terminal pro B-type natriuretic peptide (NT-proBNP) ≤ ULN (asymptomatic abnormalities may be permitted after clearance by cardiology consultation).\n11. All patients and their partners must have no plans for conception from screening period and during the trial, and agree to practice effective contraception during the trial and for 4 months after the last dose of JLM019.\n12. Able to participate and willing to give written informed consent form.\n\nExclusion Criteria:\n\n1. Allergy to JLM019 Injection components;\n2. History of Grade 4 infusion-related, anaphylactic or allergic reaction to any previous monoclonal antibody or other Fc-based protein therapy;\n3. Experienced any cardiovascular immune-related adverse event (irAE), or discontinued from that treatment due to a Grade 3 or higher irAE in previous ICI therapy;\n4. Any serious or uncontrolled health conditions listed below:\n\n   * Patients with concurrent infections requiring intravenous antimicrobial therapy within the past 2 weeks, or with unexplained fever (body temperature ≥ 37.5 °C);\n   * History of vascular diseases within the past 6 months (including myocardial infarction, unstable angina, cerebrovascular diseases, and peripheral arterial or aortic diseases);\n   * Uncontrolled hypertension (defined as systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg on at least two separate occasions after antihypertensive treatment);\n   * Individuals with active thrombosis, active bleeding, or pathological conditions associated with high bleeding risk (such as coagulation disorders);\n   * Has an active autoimmune disease that has required systemic treatment (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment;\n   * Any serious or uncontrolled cardiovascular condition, including but not necessarily limited to:\n\n     1. Any history of myocarditis of any etiology;\n     2. History of New York Heart Association Class III or IV congestive heart failure, myocardial infarction, unstable angina, cerebrovascular accident, cardiac hospitalization, or other acute uncontrolled heart disease within 6 months of scheduled C1D1;\n     3. Left ventricular ejection fraction \\\u003C 45 % on screening echocardiogram;\n     4. Any clinically significant findings on screening EKG such as atrial or ventricular arrythmia (other than sinus tachycardia) or AV conduction abnormality such as left bundle branch block (such patients may be enrolled after cardiology clearance and Sponsor approval);\n5. History of (non-infectious) pneumonitis \u002F interstitial lung disease or current pneumonitis \u002F interstitial lung disease;\n6. Presence of any active central nervous system (CNS; brain or leptomeningeal) metastases. Solid tumor patients with CNS metastases are eligible if previously treated and there is no magnetic resonance imaging (MRI) evidence of progression for ≥ 8 weeks after treatment is complete and within 28 days prior to first dose of JLM019 Injection;\n7. Prior organ allograft or allogeneic hematopoietic stem cell transplantation (HSCT). Lymphoma patients ≥ 3 months post-HSCT with no evidence of active graft versus host disease may be eligible upon approval by the Investigator or Sponsor;\n8. Receipt of any of the following within the timeframes indicated, before first scheduled dose of JLM019 Injection:\n\n   1. Checkpoint inhibitors, including PD-(L)1 (e.g., pembrolizumab, nivolumab, cemiplimab, avelumab, durvalumab), CTLA-4 (e.g., ipilimumab, tremelimumab) and Lag-3 (e.g., relatlimab), or costimulatory agonists (including but not limited to CD28, CD134 (OX40), CD137 (4-1BB)): 3 months (135 days for atezolizumab);\n   2. Chemotherapy, small molecule anticancer agents (e.g., kinase inhibitors), or radiation: 2 weeks. Note: for lung cancers or mesotheliomas, radiation therapy to the lung that is \\> 30 Gy within 6 months;\n   3. Other monoclonal antibodies, antibody-drug conjugates, bispecific antibodies, antibody-like drugs, cytokines, cell therapies, or radio immunoconjugates: 4 weeks (2 weeks permissible with documented disease progression and approval by the medical monitor or Sponsor);\n9. Currently participating in another clinical trial or has participated in another clinical trial within 4 weeks prior to the first dose of the investigational study treatment. Note: Patients who have entered the follow-up phase of another study may be enrolled if at least 4 weeks have elapsed since their last dose of study treatment;\n10. Any condition requiring systemic treatment with either corticosteroids (\\> 10 mg\u002Fday prednisone or equivalent) or other immunosuppressive medications within 14 days of the first dose of JLM019 Injection. Inhaled, intranasal or topical corticosteroids or adrenal replacement doses of corticosteroids are permitted in the absence of active autoimmune disease;\n11. Received a live or live-attenuated vaccine within 30 days prior to the first dose of JLM019 Injection. Note: Administration of inactivated vaccines is allowed;\n12. Received radiotherapy within 2 weeks of start of study treatment or had a history of radiation pneumonitis. Note: Patients must have recovered from all radiation-related toxicities, not required corticosteroids, and show no evidence of radiation pneumonitis. A 1-week washout period is permitted for palliative radiation (≤ 2 weeks of radiotherapy) to non-CNS disease;\n13. Any second malignancy active within the previous 3 years( (except adequately treated carcinoma in situ of cervix, basal cell carcinoma or squamous cell skin carcinoma));\n14. Patients with a history of AIDS, syphilis, or active hepatitis \\[For hepatitis B: positive hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) and HBV-DNA copy number above the upper limit of quantification; for hepatitis C: positive HCV antibody and HCV RNA copy number above the upper limit of quantification\\].\n15. Pregnancy or lactation, and a woman of childbearing potential (WOCBP) who has a positive pregnancy test (within 7 days) prior to treatment;\n16. Patients deemed unsuitable for participation in this study at the Investigator's discretion.",{"count":533,"type":19},115,[58],"This is a multicenter, single-arm, open-label, dose escalation phase (Part A) and dose expansion (Part B) study to evaluate the safety and tolerability of JLM019 Injection in patients with advanced malignancies.\n\nThe study subjects are adults with advanced malignancies including advanced solid tumors or relapsed\u002Frefractory lymphoma.\n\nDuring the dose escalation phase, the dose escalation scheme is the accelerated titration in 0.001 - 0.2 mg\u002Fkg cohorts plus a traditional '3 + 3' design in 0.6 - 10 mg\u002Fkg cohorts, jointly in nine dose cohorts 0.001, 0.01, 0.05, 0.2, 0.6, 1.5, 3, 6 and 10 mg\u002Fkg. JLM019 Injection is intended to be administered once a week (QW). However, the dose and interval of administration may be adjusted based on the acquired PK, PD, and safety data. Each treatment cycle is 28 days.The repeated dose is tentatively scheduled to be administered once weekly until one of the following occurs: disease progression, intolerable toxicity, requirement for new antitumor therapy, withdrawal of informed consent form, death, loss to follow-up, or other protocol-specified discontinuation conditions.\n\nSafety profile, DLT, MTD and RED of JLM019 Injection shall be assessed during and after treatment, with PK, PD, immunogenicity and Efficacy analyzed correspondingly.",[537,29,71],"Advanced Solid Tumor (Phase 1)",{"date":539,"type":36},"2026-06-03",{"date":541,"type":36},"2026-01-13",{"date":543,"type":19},"2029-07-01",{"name":545,"class":160},"Jecho Biopharmaceuticals Co., Ltd.",{"id":547,"slug":548,"hasResults":12,"nctId":549,"briefTitle":550,"officialTitle":551,"acronym":4,"eligibilityCriteria":552,"healthyVolunteers":52,"sex":16,"minAge":553,"maxAge":4,"enrollmentInfo":554,"targetDuration":4,"studyType":20,"phases":555,"briefSummary":556,"conditions":557,"keywords":4,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":570,"lastUpdatePostDateStruct":571,"startDateStruct":572,"completionDateStruct":574,"leadSponsor":576,"locationsCount":44},"100377523","phase-2-donor-stem-cell-transplant-with-treosulfan-fludarabine-and-total-body-irradiation-for-the-treatment-of-hematological-malignancies-100377523","NCT04195633","Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies","Hematopoietic Stem Cell Transplantation From Haploidentical Donors in Patients With Hematological Malignancies Using a Treosulfan-Based Preparative Regimen","Inclusion Criteria:\n\n* Acute leukemia (AL) that includes acute myeloid leukemia (AML) \u002F acute lymphoblastic leukemia (ALL) \u002F mixed phenotype leukemia (MPAL) in complete morphological remission (CR) with or without detectable minimal residual disease (MRD); complete morphological remission is defined by the presence of less than 5% of detectable blasts in bone marrow specimen, evaluated per standard of care. Patients with documented CR but without hematologic recovery since last chemotherapy are considered eligible to the study\n* Chronic myelogenous leukemia (CML), except refractory blast crisis. To be eligible in first chronic phase, patients must have failed or be intolerant to at least one tyrosine-kinase inhibitor\n* Chronic myelomonocytic leukemia (CMML)\n* Myelodysplastic syndromes (MDS)\n* Lymphoblastic, Burkitt's and other high-grade lymphoma in any complete (CR) or partial (PR) response\n\n  * CR and PR are defined according to Lugano classification: Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification\n* Low grade lymphoma (chronic lymphocytic leukemia \\[CLL\\]\u002Fsmall lymphocytic lymphoma \\[SLL\\], marginal zone lymphoma, follicular lymphoma) progressed after two treatment regimens, in CR\u002FPR\n\n  * For CLL\u002FSLL, CR and PR are defined according to: International Workshop on CLL (iwCLL) guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL\n  * CR and PR are defined according to Lugano classification: Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification\n* Large cell lymphoma in \\> second CR (CR2)\u002F \\>= PR2\n\n  * CR and PR are defined according to Lugano classification: Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification\n* Mantle cell lymphoma, lymphoplasmacytic lymphoma and prolymphocytic leukemia may be eligible after initial therapy if in CR\u002FPR\n\n  * CR and PR are defined according to Lugano classification: Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification\n  * For prolymphocytic leukemia (PLL), CR is defined as a normalization of lymphadenopathies (long-axis diameter \\\u003C 1 cm) and splenomegaly (\\\u003C 13 cm), absence of constitutional symptoms, PLL cells \\\u003C 5% in bone marrow and circulating lymphocytes count \\\u003C 4 x 10\\^9\u002FL. Patients without hematopoietic recovery are considered eligible to the study. PR is defined as a decrease of \\>= 30% of the sum of lymphadenopathies' long-axis diameters, a decrease of \\>= 50% in spleen vertical length beyond normal from baseline, peripheral blood (PB) lymphocytes =\\\u003C 30 x 10\\^9\u002FL (and a decrease of \\>= 50% from baseline)\n* Hodgkin Lymphoma in \\> CR2\u002FPR2\n\n  * CR and PR are defined according to Lugano classification: Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification\n* Subjects must be \\>= 6 months old\n* Karnofsky \\>= 70 or Eastern Cooperative Oncology Group (ECOG) 0-1 (for adults)\n* Lansky score \\>= 50 (for children)\n* Adequate cardiac function defined as absence of decompensated congestive heart failure or uncontrolled arrhythmia AND left ventricular ejection fraction \\>= 40% or shortening fraction \\> 22%\n* Adequate pulmonary function defined as absence of oxygen (O2) requirements and one of the following:\n\n  * Diffusion capacity of the lung for carbon monoxide (DLCO) corrected \\>= 70% mm Hg\n  * DLCO corrected between 60% - 69% mm Hg and partial pressure of oxygen (pO2) \\>= 70 mm Hg\n  * DLCO corrected between 50% - 59% mm Hg and pO2 \\>= 80 mm Hg Pediatric patients unable to perform pulmonary function tests must have O2 saturation \\>= 92% on room air. May not be on supplemental oxygen\n* Total bilirubin \\\u003C 2 x upper limit of normal (ULN) unless felt to be related to Gilbert's disease or hemolysis\n* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =\\\u003C 2.5 x ULN\n* Alkaline phosphatase =\\\u003C 5 x ULN\n* Creatinine \\\u003C 2.0 mg\u002Fdl (adults) or estimated creatinine clearance \\> 40 ml\u002Fmin (pediatrics)\n\n  * All adults with a creatinine \\> 1.2 or a history of renal dysfunction must have estimated creatinine clearance \\> 40 ml\u002Fmin\n* If recent mold infection, e.g., aspergillus, must be cleared by infectious disease to proceed\n* Patients who have undergone prior allogeneic hematopoietic cell transplant are eligible, but the prior transplant must have been performed at least 3 months prior to enrollment, unless in case of graft failure from the prior transplant\n* Written and signed informed consent\n* DONOR: Donors must be haploidentical relatives of the patients. Donor-recipient compatibility will be tested through HLA typing at high resolution for the HLA loci (-A, -B, -C, -DRB1, -DQB1). Donor and recipient should share at least 5\u002F10 HLA loci\n* DONOR: Age \\>= 12 years\n* DONOR: Weight \\>= 40 Kg\n* DONOR: Ability of donors younger than 18 years of age to undergo apheresis without use of a vascular access device. Vein check must be performed and verified by an apheresis nurse prior to arrival.\n* DONOR: Donor must meet selection criteria as defined by the Foundation of the Accreditation of Cell Therapy (FACT) and will be screened per the American Association of Blood Banks (AABB) guidelines\n* DONOR: In case of more available haploidentical donors, selection criteria should include, in this order:\n\n  * For cytomegalovirus (CMV) seronegative recipients, a CMV seronegative donor\n  * Red blood cell compatibility\n\n    * Red blood cell (RBC) cross match compatible\n    * Minor ABO incompatibility\n    * Major ABO incompatibility\n\nExclusion Criteria:\n\n* Active, uncontrolled, life-threatening viral, bacterial or fungal infection requiring treatment at time of conditioning regiment administration and transplantation\n* Presence of a malignancy other than the one for which the transplant is being performed, with an expected survival less than 75% at 5 years\n* Pregnant or breastfeeding\n* Known hypersensitivity to treosulfan, fludarabine or cyclophosphamide\n* Dosing with another investigational agent within 30 days prior to entry in the study\n* Central nervous system (CNS) leukemic involvement not clearing with intrathecal chemotherapy and\u002For cranial radiation prior to initiation of conditioning (day -6)\n* DONOR: Since detection of anti-donor-specific-antigen antibodies (anti-DSA) is associated with higher graft rejection rate, patients will be screened for anti-DSA pre-transplant. Patients with DSA mean fluorescent intensity (MFI) \\\u003C 5000 after desensitization treatment, will be considered eligible to participate in the study. The first 10 subjects enrolled in the trial will be DSA-negative.","6 Months",{"count":114,"type":19},[90],"This phase II trial studies how well a donor stem cell transplant, treosulfan, fludarabine, and total-body irradiation work in treating patients with blood cancers (hematological malignancies). Giving chemotherapy and total-body irradiation before a donor stem cell transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient, they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. The donated stem cells may also replace the patient's immune cells and help destroy any remaining cancer cells.",[196,62,63,558,559,442,560,561,29,67,562,563,564,68,565,566,567,568,569],"Adult Diffuse Large Cell Lymphoma","Anaplastic Large Cell Lymphoma","Chronic Myeloid Leukemia, BCR-ABL1 Positive","Chronic Myelomonocytic Leukemia","Lymphoplasmacytic Lymphoma","Mantle Cell Lymphoma","Mixed Phenotype Acute Leukemia","Prolymphocytic Leukemia","Refractory Chronic Lymphocytic Leukemia","Refractory Follicular Lymphoma","Refractory Marginal Zone Lymphoma","Refractory Small Lymphocytic Lymphoma","2026-05-27",{"date":515,"type":36},{"date":573,"type":36},"2021-01-25",{"date":575,"type":19},"2029-03-12",{"name":577,"class":43},"Fred Hutchinson Cancer Center",{"id":579,"slug":580,"hasResults":12,"nctId":581,"briefTitle":582,"officialTitle":583,"acronym":4,"eligibilityCriteria":584,"healthyVolunteers":12,"sex":16,"minAge":53,"maxAge":585,"enrollmentInfo":586,"targetDuration":4,"studyType":171,"phases":4,"briefSummary":588,"conditions":589,"keywords":4,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":688,"lastUpdatePostDateStruct":689,"startDateStruct":690,"completionDateStruct":692,"leadSponsor":694,"locationsCount":696},"100612878","social-health-activity-behaviors-and-quality-of-life-among-young-adult-cancer-survivors-100612878","NCT07259304","Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors","Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors: A Longitudinal Study","Inclusion Criteria:\n\n* Diagnosed and\u002For treated with cancer between ages 18-39 at USC hospitals.\n* Cancer types prototypical for adolescents and young adults (AYAs) and cancer stages I-III; select patients with stage IV disease may be eligible, with approval by the principal investigator (PI) and in consultation with the treating clinician.\n* Must be within three months of a de novo cancer diagnosis at recruitment and on\u002Findicated for curative therapy (any modality). Patients may continue on adjuvant therapy throughout duration of the study.\n* Patients must have anticipated survival of \\>1-year at time of diagnosis.\n\nExclusion Criteria:\n\n* Diagnosis of blood malignancies such as leukemias (these cancers have divergent treatment patterns of longer duration than other cancers and are more commonly pediatric cancers). Some early stage lymphomas with favorable prognoses may be eligible, with approval by the PI and in consultation with the treating clinician.\n* Primary language other than English or Spanish.\n* Inability to complete a survey and\u002For wear an accelerometer either per the patient or in consultation with the clinician's judgment.","39 Years",{"count":587,"type":19},250,"This study assesses how personal relationships (such as friendships, family relationships, or romantic partners) influence the physical activity (exercise) and well-being of young adult cancer survivors. Researchers also hope to learn how social relationships change after a cancer diagnosis, and how these changes might impact important health behaviors. The information provided may help researchers learn more about better ways to support young cancer patients in the future through interventions that help maintain good social relationships and health levels of physical activity.",[590,591,592,593,594,595,596,597,598,599,600,601,602,603,604,605,606,607,608,29,609,610,611,612,71,613,614,615,616,617,618,619,620,621,622,623,624,625,626,627,628,629,630,631,632,633,634,635,636,637,638,639,640,641,642,643,644,645,646,647,648,649,650,651,652,653,654,655,656,657,658,659,660,661,662,663,664,665,666,667,668,669,670,671,672,673,674,675,676,677,678,679,680,681,682,683,684,685,686,687],"Anatomic Stage I Breast Cancer AJCC v8","Anatomic Stage IA Breast Cancer AJCC v8","Anatomic Stage IB Breast Cancer AJCC v8","Anatomic Stage II Breast Cancer AJCC v8","Anatomic Stage IIA Breast Cancer AJCC v8","Anatomic Stage IIB Breast Cancer AJCC v8","Anatomic Stage III Breast Cancer AJCC v8","Anatomic Stage IIIA Breast Cancer AJCC v8","Anatomic Stage IIIB Breast Cancer AJCC v8","Anatomic Stage IIIC Breast Cancer AJCC v8","Central Nervous System Neoplasm","Clinical Stage I Cutaneous Melanoma AJCC v8","Clinical Stage IA Cutaneous Melanoma AJCC v8","Clinical Stage IB Cutaneous Melanoma AJCC v8","Clinical Stage II Cutaneous Melanoma AJCC v8","Clinical Stage IIA Cutaneous Melanoma AJCC v8","Clinical Stage IIB Cutaneous Melanoma AJCC v8","Clinical Stage IIC Cutaneous Melanoma AJCC v8","Clinical Stage III Cutaneous Melanoma AJCC v8","Malignant Bone Neoplasm","Malignant Brain Neoplasm","Malignant Solid Neoplasm","Malignant Testicular Neoplasm","Pathologic Stage I Cutaneous Melanoma AJCC v8","Pathologic Stage IA Cutaneous Melanoma AJCC v8","Pathologic Stage IB Cutaneous Melanoma AJCC v8","Pathologic Stage II Cutaneous Melanoma AJCC v8","Pathologic Stage IIA Cutaneous Melanoma AJCC v8","Pathologic Stage IIB Cutaneous Melanoma AJCC v8","Pathologic Stage IIC Cutaneous Melanoma AJCC v8","Pathologic Stage III Cutaneous Melanoma AJCC v8","Pathologic Stage IIIA Cutaneous Melanoma AJCC v8","Pathologic Stage IIIB Cutaneous Melanoma AJCC v8","Pathologic Stage IIIC Cutaneous Melanoma AJCC v8","Pathologic Stage IIID Cutaneous Melanoma AJCC v8","Prognostic Stage I Breast Cancer AJCC v8","Prognostic Stage IA Breast Cancer AJCC v8","Prognostic Stage IB Breast Cancer AJCC v8","Prognostic Stage II Breast Cancer AJCC v8","Prognostic Stage IIA Breast Cancer AJCC v8","Prognostic Stage IIB Breast Cancer AJCC v8","Prognostic Stage III Breast Cancer AJCC v8","Prognostic Stage IIIA Breast Cancer AJCC v8","Prognostic Stage IIIB Breast Cancer AJCC v8","Prognostic Stage IIIC Breast Cancer AJCC v8","Stage I Cervical Cancer AJCC v8","Stage I Colorectal Cancer AJCC v8","Stage I Differentiated Thyroid Gland Carcinoma AJCC v8","Stage I Ovarian Cancer AJCC v8","Stage I Thyroid Gland Medullary Carcinoma AJCC v8","Stage I Uterine Corpus Cancer AJCC v8","Stage IA Cervical Cancer AJCC v8","Stage IA Ovarian Cancer AJCC v8","Stage IA Uterine Corpus Cancer AJCC v8","Stage IA1 Cervical Cancer AJCC v8","Stage IA2 Cervical Cancer AJCC v8","Stage IB Cervical Cancer AJCC v8","Stage IB Ovarian Cancer AJCC v8","Stage IB Uterine Corpus Cancer AJCC v8","Stage IB1 Cervical Cancer AJCC v8","Stage IB2 Cervical Cancer AJCC v8","Stage IC Ovarian Cancer AJCC v8","Stage II Cervical Cancer AJCC v8","Stage II Colorectal Cancer AJCC v8","Stage II Differentiated Thyroid Gland Carcinoma AJCC v8","Stage II Ovarian Cancer AJCC v8","Stage II Thyroid Gland Medullary Carcinoma AJCC v8","Stage II Uterine Corpus Cancer AJCC v8","Stage IIA Cervical Cancer AJCC v8","Stage IIA Colorectal Cancer AJCC v8","Stage IIA Ovarian Cancer AJCC v8","Stage IIA1 Cervical Cancer AJCC v8","Stage IIA2 Cervical Cancer AJCC v8","Stage IIB Cervical Cancer AJCC v8","Stage IIB Colorectal Cancer AJCC v8","Stage IIB Ovarian Cancer AJCC v8","Stage IIC Colorectal Cancer AJCC v8","Stage III Cervical Cancer AJCC v8","Stage III Colorectal Cancer AJCC v8","Stage III Differentiated Thyroid Gland Carcinoma AJCC v8","Stage III Ovarian Cancer AJCC v8","Stage III Thyroid Gland Medullary Carcinoma AJCC v8","Stage III Uterine Corpus Cancer AJCC v8","Stage IIIA Cervical Cancer AJCC v8","Stage IIIA Colorectal Cancer AJCC v8","Stage IIIA Ovarian Cancer AJCC v8","Stage IIIA Uterine Corpus Cancer AJCC v8","Stage IIIA1 Ovarian Cancer AJCC v8","Stage IIIA2 Ovarian Cancer AJCC v8","Stage IIIB Cervical Cancer AJCC v8","Stage IIIB Colorectal Cancer AJCC v8","Stage IIIB Ovarian Cancer AJCC v8","Stage IIIB Uterine Corpus Cancer AJCC v8","Stage IIIC Colorectal Cancer AJCC v8","Stage IIIC Ovarian Cancer AJCC v8","Stage IIIC Uterine Corpus Cancer AJCC v8","Stage IIIC1 Uterine Corpus Cancer AJCC v8","Stage IIIC2 Uterine Corpus Cancer AJCC v8","2026-05-26",{"date":122,"type":36},{"date":691,"type":36},"2021-11-24",{"date":693,"type":19},"2027-12-31",{"name":695,"class":43},"University of Southern California",2,{"id":698,"slug":699,"hasResults":12,"nctId":700,"briefTitle":701,"officialTitle":702,"acronym":703,"eligibilityCriteria":704,"healthyVolunteers":12,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":705,"targetDuration":4,"studyType":171,"phases":4,"briefSummary":707,"conditions":708,"keywords":709,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":711,"lastUpdatePostDateStruct":712,"startDateStruct":713,"completionDateStruct":715,"leadSponsor":717,"locationsCount":719},"100446947","a-study-of-brentuximab-vedotin-in-adults-with-hodgkins-lymphoma-100446947","NCT05100056","A Study of Brentuximab Vedotin in Adults With Hodgkin's Lymphoma","Effectiveness and Safety of Consolidative Brentuximab Vedotin (BV) Treatment Administered to Hodgkin's Lymphoma (HL) Patients That Had Undergone Autologous Stem Cell Transplant (ASCT). Prospective, Multicenter, Observational Study","BV-MAZOVIA","Inclusion Criteria:\n\n1\\. Adult participant (aged greater than or equal to \\[\\>=18\\] years) that underwent or are candidates for ASCT and were enrolled in BV HL NDP receiving treatment according to the Summary of Product Characteristics for Adcetris and NDP.\n\nExclusion Criteria:\n\n1. Currently participates or plans to participate in any interventional clinical trial.\n2. Any other reason that, in the Investigator's opinion, makes the participant unsuitable to participate in this study.",{"count":706,"type":19},70,"The main aim is to check how effective BV is for treating adults with HL.\n\nStudy medication will be prescribed according to the clinic's standard practice.\n\nParticipants will visit the study clinic 5 times, once every 12 weeks. When study treatment has completed, a follow-up visit will be scheduled every 3 months during the first year and every 4-6 months during the next year.",[29],[710],"Drug Therapy","2026-05-21",{"date":570,"type":36},{"date":714,"type":36},"2022-03-08",{"date":716,"type":19},"2027-01-13",{"name":718,"class":160},"Takeda",13,{"id":721,"slug":722,"hasResults":12,"nctId":723,"briefTitle":724,"officialTitle":725,"acronym":4,"eligibilityCriteria":726,"healthyVolunteers":12,"sex":16,"minAge":53,"maxAge":727,"enrollmentInfo":728,"targetDuration":4,"studyType":20,"phases":730,"briefSummary":731,"conditions":732,"keywords":733,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":738,"lastUpdatePostDateStruct":739,"startDateStruct":741,"completionDateStruct":743,"leadSponsor":745,"locationsCount":747},"100578558","phase-2-pd-1-inhibitors-maintenance-for-chl-post-autohct-100578558","NCT06812858","PD-1 Inhibitors Maintenance for cHL Post-autoHCT","A Multicenter Prospective Phase II Study Evaluating the Efficacy and Safety of PD-1 Inhibitors Maintenance in Patients With Refractory\u002FRelapsed Classical Hodgkin Lymphoma After Autologous Hematopoietic Stem Cell Transplantation","Inclusion Criteria:\n\n* 18-70 years;\n* Diagnosis of r\u002Fr cHL with auto-HCT being performed as consolidation of 2 or later therapy lines;\n* High-risk cHL (Primary refractoriness after first-line therapy \u002F Relapse after first line therapy within 12 months \u002F PET\u002FCT-positive status at the time of auto-HCT \u002F Late relapse (\\> 12 months) with unfavourable prognosis factors (extranodal lesion and\u002For bulky and\u002For B-symptoms) \u002F More than one salvage regimen performed)\n* Complete or partial response by PET\u002FCT after auto-HSCT\n* No evidence of grade 3-4 adverse events (CTCAEs) after auto-HCT at the time of inclusion in the study;\n* Achieved recovery of peripheral blood counts after auto-HSCT (white blood cell count\\> 1 109\u002FL, absolute neutrophil count\\> 0.5 109\u002FL, platelets \\> 25 109\u002FL);\n* ECOG 0-2; The decision to include patients that do not fulfil the criteria of hight-risk cHL is made in consultation with the PI\n\nExclusion Criteria:\n\n* Patients who have received PD1-inhibitor therapy in the previous lines of treatment and had to interrupt treatment early due to the development of adverse events of therapy;\n* Severe organ failure: creatinine values more than 2 ULN; ALT, AST more than 5 ULN; bilirubin more than 1.5 ULN;\n* Respiratory failure of more than 1 degree at the time of inclusion in the study;\n* Unstable haemodynamics at the time of inclusion in the study;\n* Acute bacterial, viral or fungal infection at the time of inclusion;\n* Active autoimmune diseases (subjects with type 1 diabetes mellitus and hypothyroidism requiring only hormone replacement therapy, and skin diseases such as vitiligo, allopecia, or psoriasis that do not require systemic therapy may be eligible);\n* Pregnancy or breastfeeding, or planning pregnancy or parenthood during the study period;\n* Somatic or psychiatric pathology that prevents the signing of informed consent;","70 Years",{"count":729,"type":19},83,[90],"This phase II study is designed to determine the clinical efficacy of PD-1 inhibitors, administered as maintenance therapy after autologous stem cell transplant (autoHCT), in patients with relapsed or refractory (R\u002FR) classical Hodgkin Lymphoma (cHL)",[29],[734,735,736,737],"Classic Hodgkin lymphoma","autologous hematopoietic stem cell transplantation","nivolumab","pembrolizumab","2026-05-20",{"date":740,"type":36},"2026-05-22",{"date":742,"type":36},"2024-01-09",{"date":744,"type":19},"2030-09",{"name":746,"class":43},"St. Petersburg State Pavlov Medical University",4,{"id":749,"slug":750,"hasResults":12,"nctId":751,"briefTitle":752,"officialTitle":752,"acronym":4,"eligibilityCriteria":753,"healthyVolunteers":12,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":754,"targetDuration":4,"studyType":20,"phases":756,"briefSummary":757,"conditions":758,"keywords":4,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":760,"lastUpdatePostDateStruct":761,"startDateStruct":762,"completionDateStruct":764,"leadSponsor":766,"locationsCount":44},"100486558","phase-2-a-phase-ii-trial-of-mosunetuzumab-polatuzumab-tafasitamab-and-lenalidomide-in-patients-with-relapsed-b-cell-nhl-100486558","NCT05615636","A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL","Inclusion criteria:\n\nPatients in safety run in must meet the following criteria for study entry:\n\n* A diagnosis of relapsed CD20+ Follicular Lymphoma grade 1-3a\n* A diagnosis of relapsed CD20+ diffuse large B-cell lymphoma\n\nPatients in dose expansion must meet the following criteria for study entry:\n\n• A diagnosis of relapsed CD20+ diffuse large B-cell lymphoma\n\nPatients in each component (safety run in and dose expansion) must meet the following criteria for study entry:\n\n1. Evidence of progression or lack of response following at least 1 prior treatment\n2. Able and willing to provide written informed consent and to comply with the study protocol\n3. Age ≥ 18 years as these drugs have not yet established safety and efficacy in pediatric patients\n4. At least 1 site of measurable disease greater than 1.5cm\n5. Adequate hematologic function (unless abnormalities are related to NHL), defined as follows:\n\n   * Hemoglobin ≥ 9.0 g\u002FdL\n   * Absolute neutrophil count ≥ 1.0 x 109\u002FL\n   * Platelet count ≥ 75 x 109\u002FL\n6. Serum bilirubin \\\u003C1.5x ULN except in patients with Gilbert fs syndrome as defined by \\> 80% unconjugated bilirubin who must have a serum bilirubin of \\\u003C4x ULN; AST (SGOT) and ALT (SGPT) ≤ 3x ULN or \\\u003C 5x ULN if hepatic metastases are present\n7. Renal function assessed by calculated creatinine clearance:\n\n   . Calculated creatinine clearance ≥30ml\u002Fmin by Cockcroft-Gault formula. See section below, \"Dosing Regimen\", regarding lenalidomide dose adjustment for calculated creatinine clearance ≥30ml\u002Fmin and \\\u003C 60ml\u002Fmin.\n8. Patients must be willing to receive transfusions of blood products.\n9. For men who are not surgically sterile, agreement to use a barrier method of contraception for ≥ 3 months after the last treatment dose. In addition, male patients must agree to request that their partners use an additional method of contraception, such as oral contraceptives, intrauterine device, barrier method of contraception, or spermicidal jelly. With female partners of childbearing potential or pregnant female partners, men must remain abstinent or use a condom during the treatment period and for 60 days after the final dose of mosunetuzumab, 6 months after the final dose of polatuzumab vedotin, and 60 days after the final dose of tocilizumab, as applicable, to avoid exposing the embryo. Men must refrain from donating sperm during this same period.\n10. For women of reproductive potential who are not surgically sterile, agreement to use two adequate methods of contraception, such as oral contraceptives, intrauterine device, or barrier method of contraception in conjunction with spermicidal jelly for ≥ 12 months after the last therapeutic drug dose\n11. Females of childbearing potential (FCBP, defined as a female of childbearing potential is a sexually mature woman who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2)has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months). must have a negative serum pregnancy test with a sensitivity of at least 50 mIU\u002FmL within 10 - 14 days prior to and again within 24 hours of prescribing lenalidomide and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 4 weeks before she starts taking lenalidomide. FCBP must also agree to ongoing pregnancy testing. Men must agree to use a latex condom during sexual contact with a female of childbearing potential even if they have had a successful vasectomy. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Women must refrain from donating eggs during this same period.\n12. All study participants must be registered into the mandatory Revlimid REMS® program and be willing and able to comply with the requirements of Revlimid REMS® program.\n13. Able to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation (patients intolerant to ASA may use warfarin or low molecular weight heparin).\n\nExclusion Criteria:\n\n1. Known hypersensitivity to any study drug\n2. Prior treatment with polatuzumab vedotin\n3. Prior treatment with mosunetuzumab or other CD20-directed bispecific antibodies\n4. Prior treatment with tafasitamab and\u002For lenalidomide\n5. Autologous SCT within 100 days prior to first study treatment administration\n6. Prior treatment with CAR-T therapy within 30 days before first study treatment administration\n7. Current eligibility for autologous SCT in patients with R\u002FR DLBCL\n8. Prior allogeneic SCT\n9. Prior solid organ transplantation\n10. History of severe allergic or anaphylactic reactions to monoclonal antibody therapy (or recombinant antibody-related fusion proteins)\n11. Regular treatment with corticosteroids during the 2 weeks prior to the start of Cycle 1, unless administered for indications other than NHL at a dose equivalent to \\\u003C 20 mg\u002Fday prednisone. Treatment with systemic immunosuppressive medications, including, but not limited to, prednisone (20 mg), azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor agents within 2 weeks prior to Day 1 of Cycle 1. The use of inhaled corticosteroids is permitted The use of mineralocorticoids for management of orthostatic hypotension is permitted. Single dose of dexamethasone for nausea or B symptoms is permitted\n12. Prior systemic treatment with chemotherapy, immunotherapy, targeted and biologic therapy 4 weeks prior to C1D1.\n13. Prior treatment with radiotherapy within 2 weeks prior to C1D1. If patients have received radiotherapy within 4 weeks prior to the initiation of study treatment, patients must have at least one measurable lesion outside of the radiation field. Patients who have only one measurable lesion that was previously irradiated but subsequently progressed are eligible.\n14. History of prior malignancy within the last 2 years, except for curatively treated basal or squamous cell carcinoma of the skin and low- grade in situ carcinoma of the cervix\n15. Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the patient's safe participation in and completion of the study, or which could affect compliance with the protocol or interpretation of results including but not limited to uncontrolled hypertension, uncontrolled congestive heart failure within past 6 months prior to screening (Class 3 (moderate) or Class 4 (severe) cardiac disease as defined by the New York Heart Association Functional Classification), uncontrolled or symptomatic arrhythmias with corrected QT interval (QTc) \\> 480 msec at screening, uncontrolled diabetes mellitus, active\u002Fsymptomatic coronary artery disease, COPD, LVEF less than 40%, renal failure, uncontrolled autoimmune hemolytic anemia or idiopathic thrombocytopenic purpura active infection, history of invasive fungal infection, moderate to severe hepatic disease (Child Pugh Class B or C), active hemorrhage, laboratory abnormality, or psychiatric illness that, in the investigators opinion places the patient at unacceptable risk and would prevent the subject from signing the informed consent form. Patients with history of cardiac arrhythmias should have cardiac evaluation and clearance.\n16. Known or suspected history of hemophagocytic lymphohistiocytosis\n17. History of autoimmune disease, including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener granulomatosis, Sjögren syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis Patients with a history of autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone may be eligible. Patients with controlled Type 1 diabetes mellitus who are on an insulin regimen are eligible for the study. Patients with a history of disease-related immune thrombocytopenic purpura, autoimmune hemolytic anemia, or other stable autoimmune diseases may be eligible after review and approval by the Medical Monitor.\n18. Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) or any major episode of infection requiring treatment with IV antibiotics or hospitalization (relating to the completion of the course of antibiotics, except if for tumor fever) within 2 weeks prior to the start of cycle 1\n19. Patients with suspected active or latent tuberculosis (latent tuberculosis needs to be confirmed by positive Interferon-gamma release assay)\n20. Known or suspected chronic active Epstein-Barr virus (EBV) infection\n21. Known HIV infection. Hepatitis B or C serologic status: subjects who are hepatitis B core antibody (anti-HBc) positive and who are hepatitis B surface antigen (HBsAg) negative will need to have a negative DNA polymerase chain reaction (PCR) and must be willing to undergo DNA PCR testing during the study to be eligible. Those who are HBsAg positive or hepatitis B DNA PCR positive will be excluded. Subjects who are hepatitis C antibody positive will need to have a negative DNA PCR result to be eligible. Those who are hepatitis C DNA PCR positive will be excluded.\n22. Vaccination with live vaccines within 28 days prior to start of treatment\n23. No peripheral neuropathy ≥ grade 2 or = grade 2 with pain\n24. Pregnant or lactating females.\n25. Women of childbearing potential must have a negative serum (-human chorionic gonadotropin \\[-hCG\\]) at screening and must adhere to the scheduled pregnancy testing as required in the Revlimid REMS® program.\n26. All patients with known central nervous system involvement with lymphoma.\n27. Contraindication to any of the required concomitant drugs or supportive treatments or intolerance to hydration due to preexisting pulmonary or cardiac impairment including pleural effusion requiring thoracentesis or ascites requiring paracentesis not due to lymphoma.\n28. Patients with active pulmonary embolism or deep vein thrombosis (diagnosed within 30 days of study enrollment).\n29. Major surgery within 4 weeks of study entry, or wound that is not healed from prior surgery or trauma.\n30. History of stroke or intracranial hemorrhage within 6 months prior to study entry.\n31. Active bleeding or history of bleeding diathesis (eg, hemophilia or von Willebrand disease).\n32. Uncontrolled AIHA (autoimmune hemolytic anemia) or ITP (idiopathic thrombocytopenic purpura).\n33. Prothrombin time (PT)\u002FINR or aPTT (in the absence of lupus anticoagulant) \\>2x ULN.\n34. Concurrent participation in another therapeutic clinical trial.",{"count":755,"type":19},36,[90],"To learn if giving mosunetuzumab in combination with polatuzumab vedotin, tafasitamab, and lenalidomide can help to control relapsed\u002Frefractory FL and DLBCL.",[29,406,759],"Relapsed B-cell NHL","2026-05-19",{"date":738,"type":36},{"date":763,"type":36},"2023-04-28",{"date":765,"type":19},"2027-08-19",{"name":126,"class":43},{"id":768,"slug":769,"hasResults":12,"nctId":770,"briefTitle":771,"officialTitle":772,"acronym":4,"eligibilityCriteria":773,"healthyVolunteers":12,"sex":16,"minAge":774,"maxAge":775,"enrollmentInfo":776,"targetDuration":4,"studyType":20,"phases":778,"briefSummary":779,"conditions":780,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":781,"lastUpdatePostDateStruct":782,"startDateStruct":783,"completionDateStruct":785,"leadSponsor":787,"locationsCount":44},"100635353","phase-2-phase-2-study-of-nivolumab-plus-avd-in-pediatric-adolescent-and-young-adult-patients-with-chl-100635353","NCT07551583","Phase 2 Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHL","A Phase 2 Single Arm Study To Evaluate Safety And Preliminary Efficacy Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With Newly Diagnosed Early-Stage Non-Bulky Classical Hodgkin Lymphoma","Inclusion Criteria:\n\n1. Age ≥ 2 year to 21 years\n2. Newly diagnosed early-stage (I\u002FII) non-bulky (\\\u003C10cm) classical Hodgkin lymphoma\n3. Baseline ejection fraction must be \\> 40%\n4. Adequate hepatic function (direct bilirubin \\\u003C 1.5x upper limit of normal (ULN) unless increase is due to Gilbert's disease or lymphoma involvement, and AST and\u002For ALT \\\u003C 3x ULN unless considered due to lymphoma involvement, in which case direct bilirubin \\\u003C 3x ULN or AST and\u002For ALT \\\u003C 5x ULN will be considered eligible)\n5. Adequate renal function (creatinine clearance ≥ 30 mL\u002Fmin) unless related to disease\n6. ECOG performance status ≤2 (Karnofsky ≥60%,) (See Appendices)\n7. In the absence of rapidly proliferative disease, the interval from prior treatment to time of initiation will be at least 14 days for cytotoxic or non-cytotoxic (immunotherapy agent(s), or an interval of 5 half-lives of the prior therapy (whichever is shorter). Steroids for patients with rapidly proliferative disease is allowed before the start of study therapy, as needed, for clinical benefit and after discussion with the PI\n8. Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better as classified by PI\n9. Unless surgically or biologically sterile: Women of childbearing potential must agree to adequate methods of contraception during the study and at least 3 months for males, and 6 months for females, after the last treatment\n\n   The effects of this combination of chemotherapy on the developing human fetus are unknown. For this reason, these agents used in this trial are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. (Refer to Pregnancy Assessment Policy MD Anderson Institutional Policy # CLN1114). This includes all female patients, between the onset of menses (as early as 8 years of age) and 55 years unless the patient presents with an applicable exclusionary factor which may be one of the following:\n   * Postmenopausal (no menses in greater than or equal to 12 consecutive months).\n   * History of hysterectomy or bilateral salpingo-oophorectomy.\n   * Ovarian failure (Follicle Stimulating Hormone and Estradiol in menopausal range, who have received Whole Pelvic Radiation Therapy).\n   * History of bilateral tubal ligation or another surgical sterilization procedure.\n\n   Approved methods of birth control are as follows: Hormonal contraception (i.e. birth control pills, injection, implant, transdermal patch, vaginal ring), Intrauterine device (IUD), Tubal Ligation or hysterectomy, Subject\u002FPartner post vasectomy, Implantable or injectable contraceptives, and condoms plus spermicide. Not engaging in sexual activity for the total duration of the trial and the drug washout period is an acceptable practice; however periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.\n10. Ability to understand and the willingness to sign a written informed consent document as detailed below and if minor, getting parental\u002Fguardian consent\n\nExclusion Criteria:\n\n11\\) Patients who have received prior systemic therapy for the lymphoma with the exclusion of steroids for inflammatory conditions (e.g. asthma) or greater than 72 hours of emergent steroids (e.g. symptomatic mediastinal mass)\n\n1. Patients who weigh less than 10kg\n2. Any severe allergy to any of the drugs (Nivo-AVD)\n3. Patients with any concurrent uncontrolled medical condition, infection, laboratory abnormality, or psychiatric illness which could place the patient at unacceptable risk of study treatment\n4. Patients who are receiving any other cancer directed investigational agents; The use of other chemotherapeutic agents or anti-lymphoma agents is not permitted during study\n5. Active or prior documented autoimmune disease (including inflammatory bowel disease, celiac disease, Wegener syndrome) within the past 2 years. Subjects with childhood atopy or asthma, vitiligo, alopecia, Hashimoto syndrome, Grave's disease, or psoriasis not requiring systemic treatment (within the past 2 years) are not excluded\n6. Current or prior use of immunosuppressive medication within 14 days prior to the first dose of nivolumab. The following are exceptions to this criterion:\n\n   1. Intranasal, inhaled, topical steroids, or local steroid injections (eg, intra-articular injection).\n   2. The use of stable systemic steroid doses less than or equal to 20 mg of prednisone daily are permitted for medical conditions needing systemic steroids.\n   3. Steroids as premedication for hypersensitivity reactions (eg, computed tomography \\[CT\\] scan premedication\n\n12\\) The use of strong inhibitors or inducers of CYP1A2 (dacarbazine interaction) or CYP3A4 (doxorubicin, vinblastine interactions) should be avoided. Multiple CYP3A4 interacting agents of moderate or strong effect in the HIV+ patients should not be used. This includes most HIV protease inhibitors. 13) Known active HIV and hepatitis B and hepatitis C (unless see below points (a)(b)). Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial. Patients with prior hepatitis B and hepatitis C with are undetectable viral load are eligible for this trial.\n\n14\\) For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated\n\na. Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load\n\n7\\) Patients with psychiatric illness\u002Fsocial situations that would limit compliance with study requirements 8) Patients with a concurrent active malignancy under treatment 9) Pregnant women are excluded from this study because these agents have the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with these agents, breastfeeding should be discontinued if the mother is treated on protocol","2 Years","21 Years",{"count":777,"type":19},15,[90],"The goal of this clinical research study is to learn if nivolumab plus AVD (doxorubicin, vinblastine, and dacarbazine) can help to control newly diagnosed early-stage non-bulky cHL in pediatric, adolescent, and young adult patients.\n\nThe safety of this drug combination will also be studied.",[29],"2026-05-18",{"date":738,"type":36},{"date":784,"type":19},"2026-10-01",{"date":786,"type":19},"2032-12-31",{"name":126,"class":43},{"id":789,"slug":790,"hasResults":12,"nctId":791,"briefTitle":792,"officialTitle":793,"acronym":4,"eligibilityCriteria":794,"healthyVolunteers":12,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":795,"targetDuration":4,"studyType":20,"phases":797,"briefSummary":798,"conditions":799,"keywords":4,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":823,"lastUpdatePostDateStruct":824,"startDateStruct":825,"completionDateStruct":827,"leadSponsor":829,"locationsCount":44},"100614857","phase-2-the-cancer-connected-access-and-remote-expertise-beyond-walls-program-to-provide-in-home-cancer-treatment-and-improve-treatment-satisfaction-in-cancer-patients-living-in-the-florida-panhandle-and-surrounding-areas-100614857","NCT07285044","The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas","Cancer CARE (Connected Access and Remote Expertise) Beyond Walls - Pilot, Phase 2 Clinical Trial to Evaluate Administration of Cancer-Directed Therapy in the Patient's Homes Versus in Clinic in the Florida Panhandle and Surrounding Areas","Inclusion Criteria:\n\n* Patient has had adequate tolerability of their clinical standard of care treatment, in the opinion of their treating physician, and no clinically significant drug-related reactions occurred prior to consent\n* Participant must be receiving a standard-of-care treatment regimen listed in this protocol that is being used in accordance with standard medical practice. Specifically, it must be either a) Food and Drug Administration (FDA)-approved for the participant's disease indication, or b) recommended in nationally recognized professional guidelines (e.g. National Comprehensive Cancer Network \\[NCCN\\], American Society of Clinical Oncology \\[ASCO\\], American Society of Hematology \\[ASH\\], etc.) as standard of care for the disease indication. Off-label use is permitted only if supported by such guidelines\n* A social stability screener, used per standard of care, indicates patient is appropriate to participate in the CCBW program\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, 2 or 3 at the discretion of the treating physician\n* Female or male patients age \\>= 18 years at the time of consent\n* Willing and able to comply with the study protocol in the investigator's judgement\n* Patients with histologically confirmed malignancy who are currently receiving treatment with one of the eligible treatment regimens. Patients with hepatocellular carcinoma (HCC) are eligible based on imaging diagnosis alone: histologic confirmation is not required.\n\n  * Note: patients diagnosed with any of the following disease types may receive any of the eligible regimens listed. Additionally, patients receiving hormonal or immunotherapy, such as nivolumab or pembrolizumab, may receive these infusions in home supplemental to any of the regimens identified. Co-administration with hormonal agents such as anti-androgens, poly(ADP-ribose) polymerase (PARP) inhibitors, oral gonadotrophin releasing hormone (GnRh) antagonists, estrogens, selective estrogen receptor modulators (SERMs), or aromatase inhibitors are allowed, however combinations of oral regimens only are not permitted. Patients may receive any combination of any listed medications or regimens\n  * Eligible disease cancer types:\n\n    * Amyloidosis\n    * Basal cell carcinoma\n    * Biliary\n    * Bladder\n    * Breast\n    * Cervical\n    * Colorectal\n    * Endometrial\n    * Fallopian tube\n    * Gastroesophageal\n    * Glioblastoma\n    * Head and neck\n    * Hepatocellular\n    * Hodgkin lymphoma\n    * Lung\n    * Mantle cell lymphoma\n    * Merkle cell carcinoma\n    * Multiple myeloma\n    * Melanoma\n    * Myelodysplastic syndrome\n    * Ovarian\n    * Pancreatic\n    * Peritoneal\n    * Prostate\n    * Renal cell carcinoma\n    * Squamous cell carcinoma\n    * Urothelial carcinoma\n  * Eligible regimens\n\n    * Atezolizumab +\u002F- bevacizumab\n    * Avelumab\n    * Bevacizumab\n    * Bortezomib\n    * Cemiplimab\n    * Daratumumab +\u002F- bortezomib\n    * Darbepoetin alpha\n    * Degarelix\n    * Denosumab (Xgeva)\n    * Durvalumab\n    * Fluorouracil +\u002F- bevacizumab\n    * Fulvestrant\n    * Goserelin\n    * Ipilimumab +\u002F- Nivolumab\n    * Lanreotide\n    * Leuprolide\n    * Nivolumab\n    * Nivolumab + relatlimab\n    * Octreotide\n    * Pembrolizumab\n    * Pertuzumab +\u002F- trastuzumab\n    * Trastuzumab +\u002F- pertuzumab\n    * Zoledronic acid (Zometa)\n* Willingness to follow birth control requirements for females and males of reproductive potential\n* Resides within the Florida Panhandle and surrounding area serviced by the at-home healthcare supplier utilized for the study and a paramedic network\n* Patient's residence has an existing Wi-Fi connection or can be connected using using a mobile Wi-Fi device provided as part of the program so as to enable a reliable connection with the remote CCBW Command Center at Mayo Clinic\n* Patients who, according to documentation from their treating provider, plan to continue the eligible treatment regimen they are currently prescribed for \\>= 12 weeks from the time of registration\n* Provide written informed consent\n* Ability to complete questionnaire(s) by themselves or with assistance\n* Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)\n\nExclusion Criteria:\n\n* Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens\n* Receiving any investigational agent which would be considered as a treatment for the primary neoplasm.\n\n  * Note: oral concomitant medications for oncologic indications will be maintained per standard of care treatment and not considered part of the trial. Any nononcologic medication, regardless of route of administration will be maintained per standard of care treatment and also not considered part of the trial; therefore, patients receiving oral anti-cancer or other medications per standard of care treatment in addition to any of the medications listed are considered eligible for this trial\n* Individuals who require continuous (24\u002F7) assistance with daily living and are unable to independently manage the technology required for study participation, unless a caregiver is available and willing to provide consistent support throughout the study\n* Current inpatient hospitalization (excluding admission to the Advanced Care at Home program)",{"count":796,"type":19},27,[90],"This phase II trial studies whether providing cancer treatment in the home is preferred over the traditional clinic setting and if it improves treatment satisfaction in cancer patients living in the Florida Panhandle and surrounding areas. Typically, drug-related cancer care is provided at a medical center which causes patients to have to spend considerable time away from their family, friends, and familiar surroundings. This may add to the physical, emotional, social, and financial burden for patients and their families during this difficult time in their lives. The Cancer Connected Access and Remote Expertise (CARE) Beyond Walls (CCBW) program uses a specialized care team trained to provide cancer treatment in the patient's home setting. It is designed to support remote connection between the home health team and providers and Mayo clinic. This may be preferred over the traditional clinic setting which may improve treatment satisfaction in cancer patients living in the Florida Panhandle and surrounding areas.",[800,801,802,803,804,805,806,807,808,809,810,811,66,812,29,813,611,563,814,815,409,68,816,817,818,819,820,821,822],"Amyloidosis","Basal Cell Carcinoma","Biliary Tract Carcinoma","Bladder Carcinoma","Breast Carcinoma","Cervical Carcinoma","Colorectal Carcinoma","Endometrial Carcinoma","Fallopian Tube Carcinoma","Gastroesophageal Junction Carcinoma","Glioblastoma","Head and Neck Carcinoma","Hepatocellular Carcinoma","Lung Carcinoma","Melanoma","Merkel Cell Carcinoma","Ovarian Carcinoma","Pancreatic Carcinoma","Primary Peritoneal Carcinoma","Prostate Carcinoma","Renal Cell Carcinoma","Squamous Cell Carcinoma","Urothelial Carcinoma","2026-05-15",{"date":781,"type":36},{"date":826,"type":36},"2025-12-18",{"date":828,"type":19},"2026-12-18",{"name":830,"class":43},"Mayo Clinic"]